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ABSTRACT OF THE DISSERTATION 
 
Identification of Genetic Etiology in Disorders of Sex Development 
 
by 
 
Hayk Barseghyan 
Doctor of Philosophy in Human Genetics 
University of California, Los Angeles, 2017 
Professor Eric J.N. Vilain, Chair 
 
Disorders of Sex Development (DSD) are defined as “congenital conditions in 
which development of chromosomal, gonadal, or anatomic sex is atypical.” These 
conditions have an approximate frequency of 0.5-1% of live births and encompass a 
wide variety of urogenital abnormalities ranging from mild hypospadias to sex reversal. 
Lack of standardized anatomical/endocrine phenotyping and the limited number of 
known DSD genes with poor genotype/phenotype correlation have hampered the field 
of clinical management, leaving many patients without a definitive genetic diagnosis. 
Thus, the focus of this dissertation is to identify the underlying pathogenic genetic 
mutations that disrupt development of urogenital structures, leading to Disorders of Sex 
Development in humans. 
The traditional trend of diagnostic approach for patients with DSD is to select 
candidate gene testing by searching for additional phenotypic and metabolic information 
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through imaging studies and endocrine tests that could explain the patient’s phenotype. 
This approach is usually ineffective, costly and time-consuming. To address this issue 
and identify genetic variants leading to DSD, we utilized exome sequencing, in patients 
diagnosed with abnormal sex development. We show that exome sequencing has 
transformed the field of clinical genetic diagnosis by increasing the rate of diagnosis by 
approximately 30% and has become a method of choice for many clinicians.  
Although exome sequencing provides much higher diagnostic yields for DSD 
patients than the conventional techniques, more than half of the patients tested with ES 
still do not possess a specific genetic diagnosis. Rather, in these patients ES identifies 
hundreds of variants of unknown clinical significance (VUS). To investigate the role of 
these variants in the 46,XY subset of DSD patients, we performed gonadal gene 
expression studies in C57BL/6J-YPOS mice modeling the phenotype of human 46,XY 
individuals to identify genes important in sex development. We used these genes to 
filter VUS identified in 46,XY DSD exome negative cases. We identified 15 novel 
candidate genes with mutations in 46,XY DSD patents that may be associated with 
disease pathogenesis. 
Due to innate limitations of exonic short read sequencing, many native variants 
are not identified by exome sequencing. To this end, we utilize genome sequencing in 
conjunction with a novel genome mapping technology in order to uncover the full 
spectrum of variations present in a human genomes. Collectively, these two 
technologies provide a physical map and a base pair-level DNA resolution allowing for 
identification of novel pathogenic variants that were previously inaccessible. 
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Chapter 1 
Introduction 
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Abstract 
The Chicago Consensus Conference of 2005 defined Disorders of Sex 
Development (DSD) as “congenital conditions in which the development of 
chromosomal, gonadal or anatomic sex is atypical.” DSD diagnoses are difficult to 
establish. A lack of standardization of anatomical and endocrine phenotyping and the 
limited number of known DSD genes and genotype/correlation has long hampered the 
field, leaving many patients without a definitive diagnosis. The resulting uncertainty may 
intrinsically pose a great amount of discomfort to affected individuals and their families. 
DSD-causative genes have historically been identified thanks to positional cloning of 
disease-associated variants segregating in families or chromosomal rearrangements. 
Recent advances of chromosomal microarray and exome sequencing technologies are 
allowing for higher rates of diagnostic success for DSD patients and are changing 
clinical practice. In this review, we discuss the application of these technologies and 
their findings as an upcoming model for clinical diagnosis of DSD. We show that exome 
sequencing is a valuable tool and we propose that it should be used as a first-tier 
diagnostic technique because it allows for early identification of a genetic cause that 
may be critical for patient management. 
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The Pathways of Sex Development 
 There are many interesting biological processes occurring during embryonic 
development, but perhaps the most captivating one is the development of one’s sex. 
The significance is not only biological, as it allows deciphering of underlying 
mechanisms of reproduction, fertility and sex differences in physiology and medicine, 
but also human, allowing for better care of chronic conditions involving sex organs and 
their societal implications.  
 Sex development in humans is divided into two sequential steps: sex 
determination and sex differentiation (Figure 1-1). Sex determination refers to the 
expression of gene networks that direct the development of undifferentiated bipotential 
gonads into either testes or ovaries. The earliest evidence of differential gene 
expression within the bipotential gonads occurs when SRY is upregulated in male 
gonadal somatic cells, initiating a cascade of genetic events that lead to testicular 
organogenesis [1-3]. It was shown in mice that expression of Sry and Sf1/Nr5a1 in 
Sertoli cells initiates upregulation of Sox9 [4], which organizes Sertoli cells into testicular 
tubular cords[5]. In the absence of SRY the female-specific pathways are initiated, 
promoting development of the ovaries. While female sex determination has been 
studied to a lesser degree, several genes are known to be required for proper ovarian 
development including RSPO1 [6], WNT4 [7-9], and DAX1/NR0B1 [10]. 
Once developed, testes and ovaries secrete hormones that promote further sex 
differentiation of the body throughout embryonic development and adulthood. Hormones 
secreted from testes are essential for development of male internal (epididymis, vas 
deferens, seminal vesicles) and external (penis, scrotum) genitalia. In males, secretion 
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of anti-Müllerian hormone (AMH) by Sertoli cells stimulates regression of the Müllerian 
structures that would develop into female internal genitalia. Secretion of testosterone 
and insulin-like peptide 3 by Leydig cells promotes development of male internal 
structures and testicular descent respectively. Development of external genitalia and 
prostate is mediated by conversion of testosterone to dihydrotestosterone (DHT) by 5α-
reductase. In females, development of internal genitalia (uterus, Fallopian tubes, and 
upper third of vagina) is driven by absence of AMH and testosterone and, in the 
absence of DHT, virilization of external genitalia does not occur. 
 Anomalies in these developmental pathways lead to Disorders of Sex 
Development (DSDs), defined as “congenital conditions in which the development of 
chromosomal, gonadal or anatomic sex is atypical” [11]. Most of the genes known to 
drive sex development were identified as mutated in patients with DSD. Study of these 
disorders increases our understanding of sex differences, biology of reproduction, and 
plays a crucial role in understanding human chronic conditions affecting the sexual 
organs. 
The incidence of each discrete DSD is relatively low; however, the umbrella term 
DSD encompasses both rare and not so rare conditions, ranging from mild hypospadias 
(abnormal location of the urinary meatus) to gonadal dysgenesis (and complete 
discrepancy between sex chromosomes and external genital phenotype), affecting a 
larger population than generally assumed. The birth of a child with a DSD is believed to 
be extremely stressful for families, bringing uncertainty in regards to child’s gender, 
medical treatment and future psychosexual development [11-13]. However, evidence-
based management of these patients is lacking [14].  
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Examples of Disorders of Sex Development 
Disorders of Sex Chromosomes: 
 Sex chromosome abnormalities in DSD are primarily due to nondisjunction errors 
in paternal meiosis and are defined as sex chromosome X or Y aneuploidies. This is 
unlike other autosomal aneuploidies that primarily arise due to nondisjunction events 
during maternal meiotic division. 
Turner Syndrome 
Monosomy X, the underlying chromosomal defect in Turner syndrome patients is 
estimated to be relatively common. However, in the majority of the cases (>97%) it is 
lethal [15] and 45,X is thought to be the most frequent karyotype of spontaneous 
abortuses. The karyotype of the majority of Turner cases is 45,X with an estimated 
frequency of 1 in 2000 female births [16]. A minority of Turner cases have 46,XX 
karyotype with partial deletion on one X chromosome; mosaics of 45,X and 46,XX or 
45,5 and 46,XY. Patients diagnosed with Turner syndrome generally have short stature 
due to lack of a copy of the homeobox gene SHOX, located in the pseudoautosomal 
region of the X chromosome. Ovarian development is compromised and gonads appear 
as streak (fibrous tissue) with poorly developed follicles [17]. Lower estrogen secretion 
due to underdeveloped follicles results in delayed puberty and primary amenorrhea. In a 
patient with Turner-like characteristics, a genetics diagnosis can be achieved by 
karyotyping for either 45,X or mosaics. Fluorescent in situ hybridization (FISH) or 
chromosomal microarray (CMA) should be performed in 46,XX patients to determine if a 
deletion is present on a pseudoautosomal region of X chromosome.  
6 
 
Klinefelter Syndrome 
Klinefelter syndrome affects males and the frequency estimates are difficult to make 
because many males with this syndrome live undiagnosed [18]. The karyotype of 
affected individuals is 47,XXY. Klinefelter patients are born with normal number of 
primordial germ cells that degenerate during childhood [19]. Intellectual abilities of 
Klinefelter males may be similar to that of the general population, but possibly lower 
than their siblings’. Testes are small and show low levels of androgen production [20] 
(hypergonadotropic hypogonadism). Genetic diagnosis is generally achieved by 
karyotyping, but can also be detected by CMA [21]. 
Disorders of Hormone Synthesis or Action: 
Congenital Adrenal Hyperplasia 
Congenital adrenal hyperplasia (CAH), an autosomal recessive disorder, can affect 
both 46,XX or 46,XY individuals, with an approximate frequency of CAH is 1 in 15,000 
people. However, the DSD cases are 46,XX females, most frequently with 21-
hydroxylase (CYP21) deficiency. Mutations in 21-hydroxylase block the production of 
aldosterone and cortisol. The excess precursors are used in testosterone biosynthesis, 
which increases the degree of virilization in 46,XX females. 46,XY individuals share the 
adrenal crisis phenotype but have a more poorly described genital phenotype. They 
have no external genital anomalies, but may have precocious puberty. An additional 5% 
of 46,XX CAH cases are explained by mutations in 11β-hydroxylase (CYP11B1) needed 
for production of cortisol [22].  
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More rarely, mutations in 3β-hydroxysteroid dehydrogenase 2 (HSD3B2) or 17α-
hydroxylase (CYP17) are responsible for CAH in 46,XY individuals who present with 
ambiguous genitalia. HSD3B2 mutations cause adrenal insufficiency in both 46,XX and 
46,XY cases due to lack of production of cortisol and aldosterone and additionally 
genital ambiguity in 46,XY cases due to lack of production of testosterone.  
The phenotypes of CAH patients are rather variable ranging from highly 
masculinized females to highly feminized males. This is due to multitude of possible 
mutations in both 46,XX and 46,XY karyotypes, their severity and resulting degree of in 
utero androgen exposure. Diagnosis is generally performed using biochemical tests for 
elevation of 17-OH progesterone, but endocrine profile overlap frequently yields 
ambiguous diagnoses[23]. The genetic diagnosis is identified by either single gene 
testing or targeted sequencing of several genes. 
Androgen Insensitivity Syndrome: 
Androgen insensitivity syndrome (AIS) affects 46,XY individuals and has an 
estimated frequency of 1 in 20,000 people. Individuals with AIS have normal testicular 
development that is capable of producing normal levels of testosterone and other 
testicular hormones. However, the effects of the circulating testosterone are minimized 
by a dysfunctional androgen receptor (AR). To this day more than 300 mutations have 
been identified in AR with varying degrees of impairment of androgen binding [24]. The 
phenotypic spectrum of individuals with AIS is wide and can range from complete 
female appearance (CAIS) to minimal alteration of a typical male phenotype (MAIS). 
Individuals with partial AIS (PAIS) generally present with various degrees of genital 
ambiguity.  
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Typically, CAIS presentation is during puberty, when affected women present 
with primary amenorrhea. Further examination reveals absent uterus, testosterone 
dependent structures such as prostate, short vagina and palpable inguinal or labial 
testes. PAIS presentation is during infancy with micropenis, hypospadias, 
cryptorchidism or genital ambiguity. The diagnosis is achieved by sequencing of AR 
gene, and biochemical assays of AR function have been abandoned because of high 
variability [25]. 
Disorders of Gonadal Development: 
46,XY DSD with Gonadal Dysgenesis: 
46,XY disorders of sex development are characterized by 46,XY karyotype and 
intra-abdominal bilateral dysgenetic gonads. Individuals with complete gonadal 
dysgenesis (CGD) present with female external genitalia, hypoplastic gonads mainly 
composed of fibrous tissue, no production of sperm, AMH or testosterone, and 
presence of normal Müllerian structures such as uterus and Fallopian tubes [26]. 
Individuals with partial gonadal dysgenesis possess varying degrees of dysgenetic 
testes, ambiguous genitalia, mild to severe hypospadias, low sperm production, 
Mullerian structures ranging from mild to full development [26].  
While actual percentages are difficult to evaluate, historical data suggest that 
approximately 15% of 46,XY gonadal dysgenesis cases are due to SRY mutations or 
deletions [27-29], 13% to mutations in SF1/NR5A1 [30], and a few cases due to other 
rare genetic causes (SOX9, DAX1/NR0B1,...) leaving 70% with no known genetic 
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etiology. More recent data suggest that MAP3K1 variants may explain an additional 10-
18% [31, 32].    
46,XX Testicular DSD: 
 46,XX testicular disorders of sex development are characterized by a 46,XX 
karyotype; external genitalia ranging from ambiguous to that of a typical male; presence 
of varying amounts of testicular tissue; absence of Mullerian structures [33]. The 
incidence of 46,XX testicular DSD is approximately 1 in 20,000 individuals. Among 
46,XX testicular DSD cases, 85% have a typical male phenotype after puberty with 
normal pubic hair and penile size, but consult physicians due to delayed puberty or 
infertility. Additional 15% of cases present at birth with ambiguous genitalia [33]. The 
vast majority (80-90%) of 46,XX testicular DSD can be explained by translocations of 
SRY. The remaining 15% who carry no detectable Y material typically have ambiguous 
genitalia and no known genetic etiology [33, 34]. Recently, the chromosomal 
rearrangements such as duplication upstream of SOX9 and duplication involving SOX3, 
have been shown to be involved in 46,XX DSD [35].  
 46,XX Gonadal Dysgenesis: 
 46,XX gonadal dysgenesis is characterized by a 46,XX karyotype, normal female 
external genitalia, but impaired ovarian development. Affected individuals remain 
infantile and don’t undergo normal puberty presenting with amenorrhea and infertility in 
adulthood. The gonadal histology typically shows streak gonads bilaterally. Mutations in 
follicle stimulating hormone receptor (FSHR) in an autosomal recessive form have been 
reported in several cases [36-38]. The molecular basis for 46,XX gonadal dysgenesis 
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and primary ovarian failure (POF) remain largely unknown with an estimated diagnostic 
rate of 25% [39]. However, genes such as transcription factors (NR5A1, NOBOX, 
FIGLA, FOXL2), folliculogenesis growth factors (BMP15, GDF9, INHA), LH/FSH 
receptors and proteins important in DA repair/replication (STAG3, HFM1, MCM8, 
MCM9) have recently been identified in part due to unbiased search using exome 
sequencing [40, 41]. 
Ovotesticular DSD: 
 Formerly ovotesticular DSD (OT-DSD) was known as “true hermaphroditism”, 
which is defined by the presence of both ovarian and testicular tissue in the same 
individual. OTDSD is one of the rarest forms of DSD, and one of the most poorly 
explained mechanistically. The genetic etiology of OTDSD remains unknown for a vast 
majority of patients. 
The gonadal distribution of OT-DSD can be referred to as unilateral (ovotestis on 
one side and testis or ovary on the other), bilateral (ovotestis on each side), or lateral 
(testis on one side and ovary on the other) [42]. The most common form is unilateral, 
with ovotestis/ovary in 34%, followed by bilateral (ovotestis/ovotestis) in 29%, and 
lateral (ovary/testis) in 25%. The least frequent is unilateral with ovotestis/testis (12%) 
[42, 43] (Table 1-1).The position of the gonads in patients with OT-DSD corresponds to 
the amount of testicular tissue present, with a correlation between the degree of 
gonadal descent and the amount of testicular tissue. About half of the ovotestes are 
found in an abdominal position (with a quarter inguinal and a quarter labioscrotal), while 
almost all ovaries (85%) are abdominal and half of the testes are labioscrotal [42]. 
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The geographical distribution of OT-DSD shows an overrepresentation in Africa, 
with the number of published cases at 17 per 100 million inhabitants, followed by 
Europe at 15.3. Asia is underrepresented at 1.2 cases per 100 million and South 
America at 3.6 per 100 million [42]. 
Fertility in both males and females diagnosed with OT-DSD is significantly 
reduced. Fertility in patients diagnosed with OT-DSD is significantly reduced: two cases 
of spermatogenesis and bout a dozen pregnancies have been reported [42]. About a 
dozen cases of pregnancies in females with OT-DSD have been characterized. 
However, only half of these females were able to give birth to a healthy child [44-47]. 
Malignant tumor development was calculated to occur in less than 5% of affected 
individuals. The susceptibility of patients to development of gonadal tumors seemed to 
be independent of the individual’s karyotype [42, 43]. Sex assignment of OT-DSD has 
been historically approximately divided equally between male and female [42, 43] 
(Table 1-2). 
Analysis of the chromosomal distribution of ovotesticular DSD shows that about 
60% have an XX chromosomal complement, of whom about 10% could be explained by 
SRY translocations, leaving the majority unexplained. The remaining 40% have 46,XY, 
chimeric or mosaic 46XX/46XY, other sex chromosome mosaic, or partial trisomy 22 
karyotypes [34], and the genetic etiology is still elusive [42, 43, 48] (Table 1-3). A Y 
chromosome is more often observed when there is no ovotestis (e.g. lateral). From a 
molecular perspective, the presence of SRY explains about 10% of XX OT-DSD, and in 
some patients, it is limited to gonadal mosaicism [49]. A small subset of XY patients with 
OT-DSD carry point mutations in SRY [50]. The cases of SRY-negative OT-DSD 
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remain, for the most part, unexplained genetically. Mutations in the RSPO1 gene have 
been shown to be associated with a rare syndromic form of OT-DSD with palmoplantar 
keratosis [6], and there are some reports of partial 22q duplication (containing the 
SOX10 gene) with OT-DSD (46,XX) sex reversal with partial duplication of chromosome 
arm 22q [51]. It seems clear, however, that both SRY-positive and SRY-negative OT-
DSD and testicular DSD (T-DSD) are part of the same clinical spectrum, as OT-DSD 
and T-DSD can be observed in the same family, and with the same causative genotype, 
such as the presence of a translocated SRY gene [52, 53]. The non-random inactivation 
of the SRY-bearing X chromosome has been proposed as an explanation for OT-DSD 
in SRY-positive XX OT-DSD [54]. 
Animal models of OT-DSD 
Since additional genetic factors explaining OT-DSD are yet to be identified, 
mouse models may become invaluable to this process. C57BL/6J (B6) mice containing 
the Mus domesticus poschiavinus Y chromosome, YPOS, develop ovarian tissue, 
whereas testicular tissue develops in DBA/2J or 129S1/SvlmJ (129) mice containing the 
YPOS chromosome. C57BL/6J-YPOS fetuses develop gonads varying from ovary to 
ovotestis, and constitute an excellent model of OT-DSD. To identify novel genes 
involved in sex determination, our lab used a congenic strain approach to determine 
which chromosomal regions from 129S1/SvlmJ provide protection against sex reversal 
in XYPOS mice of the C57BL/6J.129-YPOS strain. Genome scans using microsatellite 
and SNP markers identified a chromosome 11 region of 129 origin in C57BL/6J.129-
YPOS mice [55]. To determine if this region influenced testis development in XYPOS 
mice, two strains of C57BL/6J-YPOS mice were produced and used in genetic 
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experiments. XYPOS adults homozygous for the 129 region had a lower incidence of 
sex reversal than XYPOS adults homozygous for the B6 region. In addition, many 
homozygous 129 XYPOS fetuses developed normal-appearing testis, an occurrence 
never observed in XYPOS mice of the C57BL/6J-YPOS strain. It was concluded that a 
chromosome 11 locus derived from 129Sl/SvlmJ protects against sex reversal in 
XYPOS mice. Further back-crossing of C57BL/6J.129-YPOS with C57BL/6J mice 
combined with bioinformatics approaches based on sequence conservation allowed 
refinement of the critical region of chromosome 11 protecting against XY sex reversal. 
Candidate genes generated by this mouse model, combined with other genetic 
approaches involving human cases of OT-DSD will help elucidate the biology of OT-
DSD (See chapter 3). Other animal models of OT-DSD have been described, and could 
also help the identification of molecular mechanisms of this rare condition [56, 57]. 
OT-DSD is a rare condition affecting gonadal development and, although it has 
fascinated generations of clinicians and scientists, it remains mysterious in terms of 
molecular and genetic mechanisms. It is likely, however, that the advances in next-
generation sequencing, with the possibility of performing whole exome sequencing 
rapidly and at a relatively low cost [58], will eventually allow investigators to understand 
the development of both testicular and ovarian tissue in the same individual, and 
therefore allow for rapid diagnosis. 
Current Genetic Diagnostic Practice 
 The typical trend of diagnostic approach for patients with DSDs, who present in 
clinic with atypical features that do not match their genotypic sex, is to search for 
additional phenotypic and metabolic information through imaging studies and endocrine 
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tests. This type of approach helps clinicians select candidate gene for testing that could 
explain the patient’s phenotype. This is usually inefficient as phenotypes frequently 
overlap and phenotype/genotype correlations are still poor. Thus, the current standard 
of genetic diagnosis of DSDs relies on sequential sequencing of genes, handpicked as 
likely candidates for the given phenotype, performed after imaging and endocrine 
exploration is exhausted, an ineffective, costly, and time-consuming practice. Genetic 
testing is also sometimes viewed by providers – and insurance – as dispensable. Due to 
these limitations, many patients do not receive a definitive clinical diagnosis.   
The developing diagnostic practice focuses on using next-generation sequencing 
and chromosomal microarray (CMA) techniques to identify causative mutations or copy-
number variants (CNVs) that would guide the diagnostic process (Figure 1-2). Genetic 
testing would be performed alongside urgent metabolic tests that may be needed to rule 
out the life-threatening condition Congenital Adrenal Hyperplasia. The benefits of using 
these genetic diagnostic tools are twofold. From the practitioner’s perspective, these 
tools will allow for a greater diagnostic specificity and shorter turnaround times. They 
permit detection of mutations, microdeletions and microduplications for known and 
novel genes, which allows for better classification and more precise outcome studies. 
Advantages also include noninvasiveness, opposed to hormonal stimulation tests used 
to test the responsiveness of a specific biosynthetic pathway – which may modify the 
phenotype of a patient in a way that may be discordant with the chosen gender. 
Moreover, by knowing the genetic diagnosis, physicians will be able to monitor risks 
associated with a particular genotype avoiding unnecessary, costly and invasive 
exploratory endocrine or imaging tests. Rather, a limited number of these tests will be 
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specifically guided by the genetic findings. From the patient’s perspective, it will serve 
as a shortcut to the long, potentially stressful waits for diagnosis experienced by 
families. It will also be critical for genetic counseling, reproductive options and 
associated risks.  
Diagnostic Capabilities of Chromosomal Microarrays 
In comparison with classical karyotyping techniques, the high-resolution scanning 
of the entire genome afforded by chromosomal microarrays (CMA) has advanced the 
field of genetic diagnosis with increased precision[59].  
Two types of microarrays, Comparative Genomic Hybridization (CGH) and 
Single-Nucleotide Polymorphism (SNP) arrays, have been used in genetic testing to 
detect chromosomal defects. Array CGH uses direct comparison of the genomic DNA 
sample to be tested with a control. Hybridization of these two samples, labeled with 
different fluorescent tags, to an array of cloned genomic DNA fragments allows 
visualization of CNVs, micro-deletions or micro-duplications. In SNP arrays a single, 
fluorescently labeled DNA sample is hybridized to an array of synthetic oligonucleotides 
representative of the genome and the relative intensities of the test sample are 
compared to those of a pool of control samples available on the web. Due to uneven 
distribution of SNPs throughout the genome, SNP arrays initially did not have a uniform 
coverage; however, addition of additional oligonucleotide probes allowed for an 
increased genomic coverage. Recently, manufacturers combined these techniques, 
which now allow for detection of CNVs as well as regions of heterozygosity and 
homozygosity, with increased precision.  Detection of CNVs in genomic regions with 
known DSD genes can dramatically increase chances for definitive genetic diagnosis or, 
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if CNVs are identified in regions with genes not known to be involved with DSDs, it 
could facilitate identification of novel genes involved in sex development.  
For example, CNVs of DAX1/NR0B1 are a known cause of DSD: deletions cause 
Adrenal Hypoplasia Congenita and Hypogonadotropic Hypogonadism [60] while 
duplications cause 46,XY DSD with complete gonadal dysgenesis [61]. CMA is now 
able to routinely identify cases of duplications of the X chromosome that include 
DAX1/NR0B1 gene in patients diagnosed with the latter phenotype [62, 63]. 
Another example of diagnostic success of CMA is the  validation of the candidate 
gene SOX3 as an etiology in 46,XX DSD. Previously, SOX3 had not been associated 
with DSD because mutations did not result in anomalies of sex determination either in 
humans or mice [64]. However, ectopic expression of Sox3 in gonads of transgenic 
mice caused sex reversal of XX animals to phenotypic males, suggesting a dosage-
dependent effect of this gene in sex determination [65]. CMA screening of human SRY-
negative XX males identified SOX3 duplications in several patients [65], a finding 
confirmed in another two recent clinical case reports [66, 67]. These reports strongly 
suggest that increased expression of SOX3 is sufficient to drive the male sex 
determination pathway in the absence of SRY.  
Routine use of CMA analysis in clinical practice can also potentially identify novel 
candidate genes as well as CNVs in gene regulatory regions of known DSD-associated 
genes, which are not scrutinized when sequencing coding regions. A recent case report 
identified a deletion in the WWOX gene in a 46,XY DSD patient with ambiguous 
genitalia and gonadal germ line tumors [68]. Although WWOX had not been previously 
associated with DSDs, a knockout mouse model showed abnormal gonad development 
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[69], which led to the genetic diagnosis. CNVs identified outside of coding regions of the 
genome that are close to known genes involved in DSDs could be important, previously 
unrecognized, regulatory sequences that affect gene expression. For example, array 
CGH identified deletions upstream of the SOX9 gene open reading frame region, as the 
etiology of 46, XY gonadal dysgenesis [63, 70] and very small duplications in 46,XX 
Testicular and Ovotesticular DSD [71-73]. Increasingly refined SNP arrays are helping 
delineate these upstream sequences necessary for correct testis-specific regulation of 
SOX9 [72].  
To date, microarrays have yielded dozens of candidate regions whose CNV may 
cause DSD. In addition to SOX9, DAX1/NROB1, SOX3, WWOX described above, 
deletion of 9p24, including the DMRT1 gene [62, 74-76] and duplication of VAMP7 in 
Xq28 [77] are well documented. Other regions await validation [62, 74-76]. 
 CMAs are becoming increasingly used by clinics for many patients. In a study of 
23 patients diagnosed with 46, XY gonadal dysgenesis, likely causative CNVs were 
identified in 3 cases [63]. In a different study of a cohort of 16 SRY-negative XX males 
screened by CMAs, likely causative CNVs were identified in 3 patients [65]. Taken 
together, these and other studies suggest that approximately 15% of DSDs may be 
caused by CNVs. Higher rates may be seen in syndromic than isolated forms of 46,XY 
gonadal dysgenesis (25% vs 5.6%, respectively) [62]. In a cohort of 116 patients that 
included patients with only hypospadias and/or cryptorchidism (and no further complex 
genitalia), less profound differences were observed: non-polymorphic, potentially 
clinically significant CNVs were found in 17% of isolated and syndromic cases of 
hypospadias, 18% of isolated vs. 30% of syndromic cryptorchidism, and 28% isolated 
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vs. 16% syndromic ambiguous genitalia [76]. Actual rates are likely to be refined as 
methods evolve to allow identification of smaller CNVs and more genomes are 
analyzed, facilitating the accuracy of more polymorphic vs. pathogenic variant calls. 
New Diagnostic Practice: Next-Generation Sequencing Technologies 
Although CMA has proved to be a useful diagnostic technique for detecting 
chromosomal abnormalities with higher precision than traditional karyotype, it is 
ineffective for detection of small genetic variations (the current cutoff for clinical CMA 
reporting is 50 kb). Next-generation sequencing technologies have dramatically 
decreased both the cost and turnaround time for whole-genome and exome sequencing  
revolutionizing the diagnostic methods for complex disorders [78, 79]. Exome 
sequencing covers approximately 95% of the RefSeq protein-coding regions of the 
genome, which currently harbor 80-90% of known disease-causing variants [80]. 
Advantages of this approach are that all genes involved in sex development can be 
analyzed simultaneously and newly discovered genes can be easily included in the 
analysis without re-sequencing the sample. 
The UCLA Clinical Genomics Center has performed exome sequencing on 90 
research and 35 clinical DSD proband samples. For clinical samples, we utilize two 
gene lists to filter variants specifically in genes of interest. The primary gene list 
contains genes that have been shown to cause at least one published case of human 
DSD (Table 1-4). The secondary gene list contains genes that are more loosely related 
to sex development. For example data may only exist from animal models or the Online 
Mendelian Inheritance of Man (OMIM) description contains keywords related to sex 
development. Following American College of Medical Genetics and Genomics (ACMG) 
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guidelines [81], the Center reports variants when pathogenic (previously reported in 
humans as the recognized cause of the disorder) or likely pathogenic (previously 
unreported in a known human DSD gene and of a type expected to cause the disorder). 
In addition, variants of unknown significance (VUS) in genes of the secondary gene list 
are frequently reported with the expectation that these might help guide the ordering 
physician’s further imaging and endocrine exploration. 
For research samples, in addition, we search for significant variants outside the 
DSD gene lists. Since on average, a single exome sample generates around 20,000 
variants compared to reference genomes, it is most effective to perform WES of the 
patient as a trio, with phenotyped parents (for example to identify inherited vs. de novo 
variants [82]), which may increase the diagnostic capabilities of WES by almost 10% 
when compared to proband-only cases [78]. Generally, the ability of WES to provide an 
accurate genetic diagnosis heavily relies on the existing literature, good clinical 
assessment and presence of parental samples. 
 At UCLA, all cases are reviewed at a weekly Genomic Data Board meeting, 
attended by clinical geneticists, genetic counselors, sequencing laboratory personnel, 
researchers and, if available, the ordering physician to discuss the relevance of exome 
variants in each case before clinical report [78].  
Diagnostic Capabilities of Exome Sequencing 
Several clinical WES laboratories around U.S. have reported greater diagnostic 
yields when using exome sequencing than using traditional molecular diagnostic 
methods such as single gene testing or panels [78, 79]. The diagnostic rate of exome 
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sequencing at UCLA’s Clinical Genomics Center ranged from 22% (single cases) to 
31% (trio cases) in a cohort of 814 consecutive cases [78]. Similar diagnostic rates were 
seen at BCM’s Human Genome Sequencing Center, where the overall diagnostic rate in 
a cohort consisting of 504 patients was 25.2% [79]. The diagnostic rates for different 
phenotypic groups had a greater variability and ranged from 13% to as high as 48% [78, 
79, 83-85]. In many cases the precise genetic diagnosis has altered the medical 
treatment and management. 
A recent report by our laboratory illustrates the power of exome sequencing in 
terms of its diagnostic capabilities and ability to guide DSD patient management [31]. 
We studied a cohort of 40 DSD patients with a 46, XY karyotype, either clinical samples 
sent to the UCLA Clinical Genomics Center or research samples from our laboratory. 
Most of the latter had previously undergone extensive, unsuccessful, endocrine and 
genetic testing including single-gene and SOX9 promoter sequencing as well as CMA.  
In that cohort, we were able to identify a significant variant in the primary gene 
list in half of the samples, including a pathogenic variant in a quarter of them, and 
another 10% that received a likely pathogenic call. Exome sequencing identified rare, 
sometimes unsuspected genetic causes of DSD, including novel variants and diagnostic 
variants in genes for which individual gene testing was not available on a clinical basis 
in the US. For these patients, this dramatically streamlined the diagnosis process and, 
most importantly, in several cases, the early genetic diagnosis was critical to orient 
clinical management. 
For example, patients presenting clinical evidence of androgen resistance or 
insensitivity (AIS), i.e. male levels of testosterone, yet female genitalia, constitute a 
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genetic diagnostic challenge. Those who have complete AIS typically have mutations in 
the androgen receptor [86]. However, those with various degrees of androgen 
insensitivity often don’t, and genetic diagnosis is rarely achieved [87]. In the subset of 
patients with a working diagnosis of partial androgen insensitivity (PAIS), we found 
diagnostic variants in 4 different genes with very different prognoses. Only one of these 
suggested true androgen insensitivity, a novel, likely pathogenic variant in the androgen 
receptor [31]. 
In two women with suspected PAIS and inguinal gonads, exome sequencing 
generated a diagnosis for a very rare condition, often misdiagnosed as PAIS, HSD17B3 
deficiency. One was compound heterozygote for known published pathogenic variants 
in HSD17B3. The other carried a homozygous deletion including exon 1. As WES is not 
intended to detect larger deletions, an external laboratory confirmed the presence of a 
461-bp deletion, too small to be reportable with CMA on a clinical basis. In these cases, 
early genetic diagnosis was critical, because individuals with HSD17B3 deficiency are 
not actually androgen-resistant, and these young girls are at risk for virilization at 
puberty, when production of testosterone and DHT spikes. In these patients, the 
traditional diagnostic approach had either failed or been inapplicable. One patient had 
been tested for SRY presence, AR mutations and Sertoli cell function, none of which 
resulted in a diagnosis. The other patient came to the attention of a U.S. team at age 7. 
Response to androgen tests would not be performed to avoid masculinization in a 
patient with established female gender and sex of rearing. In any case, hCG stimulation 
testing to assess testosterone synthesis pathway function would not have been 
informative as she had already undergone bilateral gonadectomy. 
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In that cohort, exome sequencing also allowed to make a diagnosis of Leydig 
Cell Hypoplasia, caused by a homozygous nonsense mutation in LHCGR. LHCGR 
codes for the receptor for the brain-derived hormones that control the maturation of 
testosterone-producing Leydig cells in the testis. This very rare syndrome had not been 
suspected and this brought closure to a very long diagnostic odyssey for this family. In 
this case, years of traditional diagnostic testing had not yielded a plausible result, 
introducing anxiety and uncertainty to the patient’s and family’s lives. 
Finally, we identified a missense variant in NR5A1/SF1, a gene associated with a 
wide range of DSD phenotypes [88, 89]. This particular variant had previously been 
reported in a male with isolated distal hypospadias, generally considered a mild form of 
DSD [90]. This turned out to be extraordinarily important for this patient. She had been 
raised as female, but did not feel comfortable in that role. The original diagnosis of AIS 
meant that she would be unlikely to respond to testosterone treatment but, having self-
administered testosterone, she felt she had responded to it. The finding of an NR5A1 
variant previously reported in a male was very reassuring, supported her feeling that 
she should be male and, ultimately, her transition to a male body habitus. 
The early genetic diagnosis offered by exome sequencing is an invaluable tool 
for such cases where the candidate gene approach is ineffective and early diagnosis is 
critical to optimal patient management. We would like to propose that, outside of the 
cases of medical emergency, exome sequencing (with chromosomal microarrays in 
cases of syndromic DSD) should be considered as a first-tier diagnostic or rule/out 
diagnosis tool for DSD, and be used to guide further imaging and endocrine exploration. 
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Targeted panels using next generation sequencing have also proven to be very efficient 
diagnostic tools [91]. 
These data show that exome sequencing is capable of providing DSD patients 
with early genetic diagnosis that may be critical for their clinical management and life-
long choices. These data also show that exome sequencing can and should be used as 
a diagnostic tool and not only as a research tool, an argument generally used by US 
insurance companies to deny coverage.  
At this time, insurance coverage is often denied for the clinical exome 
sequencing, on the grounds that it may bring information important for research or for 
reproductive options for the family, but not for actual management of the individual 
patient. Exome sequencing has now been available on a clinical basis in the US for 5 
years. Hopefully, the examples above will help dispel this misconception and allow 
generalization of the practice of exome and, in a close future, whole-genome 
sequencing. 
Ethical Considerations and Future Directions  
When sequencing the genome of an individual with a certain disorder there is a 
possibility that some variants will be identified in genes not related to the condition for 
which the patient is referred. The current guidelines from ACMG for so-called “incidental 
findings” are to report pathogenic and likely pathogenic mutations in a selected list of 
high-penetrance, potentially lethal conditions for which other diagnostic methods and 
medical interventions are available to the ordering clinician regardless of patients’ age 
[92]. The same guidelines apply for sequencing of unaffected parents as part of a “trio” 
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sequencing. This practice has however been controversial (e.g. [93]) and, currently, the 
UCLA consent form asks families whether or not they would like to be informed of any 
medically actionable incidental finding. Recently, the ACMG has recognized this as a 
valid approach as well [94]. This practice is likely to evolve as the field continues to 
grapple with these ethical considerations. 
It is not always that exome sequencing will yield a genetic diagnosis. A negative 
exome could be due to several reasons. Firstly, our ability to interpret the pathogenicity 
of variants identified in known or new genes not previously associated with DSD may 
require further, extensive functional studies (such as in vivo/ex vivo gene knock-
out/knock-in animal studies or in vitro cell cultures to assess gene variant pathogenicity) 
as well as RNA sequencing from human tissues to asses differential gene expression 
changes that may be due to identified variants. Secondly, we are reaching the limits of 
understanding complex conditions by looking only at single genes, when the etiology 
could be multigenic (which is possible to investigate using exome data on a research 
basis) or multifactorial. Finally, it is likely that the genetic cause of some DSD may 
reside in non-coding regions of the genome. These will have to be explored by whole-
genome sequencing and other emerging technologies identifying structural variants of 
the genome. 
Next-generation sequencing technologies may also have an impact on our 
understanding of genotype/phenotype correlation of conditions because they can detect 
variants in multiple DSD-associated genes without a preconceived idea of the 
phenotypic spectrum associated with reported mutations in a given gene. For example, 
we identified the same pathogenic MAP3K1 variant previously described in a familial 
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case of 46,XY pure gonadal dysgenesis [32] in an individual with an ovotestis [31]. 
Variants in MAP3K1 are thought to act by shifting the signaling network from pro-male 
(Sox9/Fgf9) to pro-female (Wnt/beta-catenin) [95], but it had not previously been seen in 
an individual with an ovotestis.  
In a sort of “virtuous cycle,” the increased prevalence of exome and genome 
sequencing in clinical practice will improve the diagnostic yields of clinical next-
generation sequencing. As more genomes are sequenced, associated with detailed 
phenotyping, our understanding of phenotype/genotype correlation will progress, 
allowing for a greater diagnostic yield from exome sequencing for single-gene or 
complex diseases. 
All these considerations highlight the need for deep phenotyping and better 
genotype/phenotype correlation in DSD. To this end, we and others (see 
acknowledgements) have created the DSD-Translational Research Network, an 
NICHD-funded network of clinics and research centers, informed by patient advocates. 
Its overarching goal is to generate evidence for and promote best practices in DSD care 
to achieve best possible health outcomes and quality of life for patients and their 
families. The DSD-TRN has created the first DSD registry in the US to collect 
standardized clinical practice data and standardized measurements in all fields involved 
in clinical care for DSD families: genetic, psychosocial, endocrine, anatomy/surgery, etc. 
Data entered into the registry from all the network’s sites will be analyzed to try to derive 
new genetic etiologies for DSD, refine genotype/phenotype correlations and, eventually 
offer evidence-based recommendations for optimal practice. 
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The current/upcoming genetic diagnostic practice that consists of chromosomal 
microarrays and exome sequencing as a first line test (after life threatening conditions 
have been ruled out by endocrine tests) is the most effective method to screen patients’ 
genome for CNVs, known DSD genes, and in some cases suggest additional causative 
variants in genes previously not associated with DSDs. This practice, involving genetics 
at the heart of DSD diagnostic practice, provides a path towards acceleration of clinical 
diagnosis and improvement of patient care.  
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Figures and Tables: 
Figure 1-1: Overview of sex determination and differentiation in humans 
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Figure 1-2: Inclusion of genomic technologies in genetic diagnostic practice for DSDs 
 
 
 
Table 1-1: Gonadal distribution of ovotesticular DSD relative to the presence or 
absence of Y chromosome 
 
 
 
Without Y 
 
With Y 
 
Total 
Unilateral 
Ovotestis/Ovary         Ovotestis/Testis 
Bilateral 
Ovotestis/Ovotestis 
Lateral 
Ovary/Testis 
 
107 (27%) 
 
31 (8%) 
 
138 (34%) 
 
29 (7%) 
 
19 (5%) 
 
48 (12%) 
 
96 (24%) 
 
19 (5%) 
 
115 (29%) 
 
42 (10%) 
 
58 (14%) 
 
100 (25%) 
Note:  Table generated from combined data of [43, 96] 
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Table 1-2: Sex assignment of ovotesticular DSD relative to the presence or absence of 
Y chromosome 
 
 
 
Male (54%) 
 
Female (46%) 
 
Total 
 
Without Y 
 
With Y 
 
Total 
 
115 
 
110 
 
225 
 
63 
 
42 
 
105 
 
178 
 
152 
 
330 
Note:  Table generated from combined data of [43, 96] 
 
Table 1-3: Chromosomal distribution of ovotesticular DSD 
Case Reports 
(1970-1992) 
 
n 
 
% 
 
 
XX 
 
Mosaic with Y 
 
XY 
 
277 
 
89 
 
40 
 
65% 
 
21% 
 
9% 
 
Note:  Table generated from combined data of [43, 96] 
 
 
 
 
 
 
Table 1-4: Primary gene list used for variant filtration identified in exome 
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Abstract 
The Chicago Consensus Conference of 2005 defined Disorders of Sex 
Development (DSD) as “congenital conditions in which the development of 
chromosomal, gonadal or anatomic sex is atypical.” DSD diagnoses are difficult to 
establish. A lack of standardization of anatomical and endocrine phenotyping and the 
limited number of known DSD genes and genotype/correlation has long hampered the 
field, leaving many patients without a definitive diagnosis. The resulting uncertainty may 
intrinsically pose a great amount of discomfort to affected individuals and their families. 
DSD-causative genes have historically been identified by positional cloning of disease-
associated variants segregating in families or chromosomal rearrangements. Recent 
advances of chromosomal microarray and exome sequencing technologies have 
allowed for higher rates of diagnostic success for DSD patients and are changing 
clinical practice. Here, we use exome sequencing to identify the pathogenic variants in 
DSD cases. We show that a much higher diagnostic yield is reached when using exome 
sequencing rather than the conventional single gene testing. 
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Introduction 
 
Disorders of Sex Development (DSD) are defined as “congenital conditions in 
which development of chromosomal, gonadal, or anatomic sex is atypical” [1, 2]. 
Individuals with DSD have a discordance between their phenotypic and genotypic sex. 
Their gonads are usually abnormally developed and are described as dysgenic. The 
incidence of each discrete DSD is relatively rare; however, the umbrella term DSD 
encompasses both rare and not so rare conditions, ranging from mild hypospadias to 
sex reversal with genital ambiguity affecting a larger population than generally 
assumed. The birth of a child with a DSD is believed to be extraordinarily stressful for 
families, bringing uncertainty in regards to child’s gender and future psychosexual 
development [1, 3, 4].  
These disorders are difficult to diagnose because little is known about their 
pathogenesis. When detected at birth by malformation of the genitalia, they are typically 
considered to be a medical and social emergency, since in many cases decisions about 
gender assignment, medical treatment and surgery have to be made. Moreover, 
evidence based management of these patients is lacking [5]. At present, a specific 
molecular diagnosis is identified in only a minority of DSD patients, leaving the majority 
of DSD cases unexplained [6-8]. This suggests the existence of a number of unknown 
sex determining genes. 
 When a patient presents in clinic with a genital malformation or phenotype that 
does not match the chromosomal sex, the current trend of care (although not universal 
practice yet) calls for investigation of a potential chromosomal defect, using array CGH 
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(Comparative Genomic Hybridization). This technique uses two DNA samples, the 
patient DNA and control genomic DNA that are hybridized to the array, and the relative 
fluorescence signals of labeled DNA show regions of gain or loss of genetic material of 
the patient sample in direct comparison with the control sample. This array is 
considered the best for detecting gain or loss of genetic material and helps significantly 
with diagnosis by revealing abnormal copy numbers in regions with known DSD genes. 
However, this method does not offer clear diagnostic help when deletions/insertions are 
found in regions of unknown involvement in DSD. Additionally, findings that are smaller 
than 50kb are unlikely to be included in a clinical report due to inability to interpret the 
pathogenic significance. The cost for such test is approximately $1,500, but may vary 
widely based on a test type and institution. Based on the array results, clinician may 
suspect involvement of a particular gene associated with sex determination. Although 
our knowledge of sex determining genes has increased, only limited number of them 
are available for clinical testing, and a single gene sequence can cost up to $1,500, 
depending on the length and complexity of the target [9]. Thus, the current standards for 
genetic diagnosis of DSDs are limited to genotyping of one or two genes, chosen as 
likely candidates based on disease phenotype. Because of this narrow scope and 
exclusion of unknown genes, large numbers of patients do not receive a molecular 
diagnosis. 
Statistical models for identifying new mutations in unknown genes require 
collection of either a sample of dozens of families with an identical phenotype and at 
least two affected members (linkage analysis), or thousands of unrelated patients and 
controls (genome-wide association studies). Due to the nature and frequency of DSD, 
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neither approach has proven feasible. However, Next Generation Sequencing (NGS) 
technologies have a higher potential for diagnostic capabilities in genetics. NGS is 
capable of sequencing the entire human genome in a matter of days and also allows for 
a rapid sequencing of smaller selections of DNA by targeted capture of specific set of 
genes or the entire subset of the genome that is expressed (exome). Here, we use 
exome sequencing to identify pathogenic variants in patients diagnosed with DSD. This 
approach improves significantly the limited traditional medical diagnosis, while offering a 
realistic program for identifying new mutations or disease genes.  
Methods 
DNA isolation and sequencing 
DNA was isolated from peripheral blood Gentra Puregene Blood Kit (Qiagen, 
Germantown, MD, USA) or saliva collected using ORAgene Discover ORG-500 
(DNAgenoteck Ottawa, ON, Canada). Sequencing libraries were created for each 
individual sample following manufacturer’s protocol (Illumina protocol Preparing 
Samples for Sequencing Genomic DNA, p/n 11251892 Rev. A). Exomes were captured 
using Agilent SureSelect All Exon 50Mb capture kit and and Nextera Rapid Capture 
(Illumina, San Diego, CA USA) Sequencing was performed on an Illumina HiSeq2000 or 
HiSeq2500 as 50bp or 100bp paired-end run at the UCLA Clinical Genomics Center. 
The base-calling will be performed using the real-time analysis (RTA) software provided 
by Illumina. 
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Exome analysis 
The sequence reads (QSEQ or FASTQ files) were aligned to the human 
reference genome (hg_g1k_b37 assembly) using Novoalign V2.07.13 from the 
Novocraft Short Read Alignment Package (http://www.novocraft.com/index.html) or 
using BWA (Burrows-Wheeler Alignment Tool) [10]. The output BAM files were sorted 
merged and PCR duplicates were removed using Picard (http://picard.sourceforge.net/). 
INDEL (insertions and deletions) realignment and recalibration were performed using 
Genome Analysis Took Kit (GATK) from the Broad Institute 
(http://www.broadinstitute.org/gatk/). In the past we have reached a mean coverage of 
over 80x for each sample and approximately 93% of the RefSeq gene coding regions 
+/-2bp was covered at 10x or greater. Both single-nucleotide variants (SNVs) and small 
INDELs were called within the Ensembl coding exonic intervals +/-2bp using GATK’s 
Unified Genotyper and recalibrated and filtered using GATK variant-quality score 
recalibration and variant filtration tools. Consanguinity analysis was performed to 
identify regions > 100kb of homozygosity using Plink software 
(http://pngu.mgh.harvard.edu/~purcell/plink/). All high-quality variants were reported and 
annotated using Variant Annotator X (VAX), a custom-designed using Ensembl variant 
effect predictor [11] or VarSeq Variant Annotation, Filtering and Interpretation Software 
(Golden Helix, Inc., Bozeman, MT, www.goldenhelix.com). All variants were filtered by 
minor allele frequency (MAF) of <1% and intersected with the DSD gene list to identify 
mutations in known DSD genes.  
.  
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To assess previously unreported missense variants we used three in silico 
algorithms SIFT [12], PolyPhen [13] and Condel [14]. These algorithms predict the 
likelihood that a given missense variant is pathogenic, based on conservation of the 
amino acid across species, the physical characteristics of the altered amino acid and 
the possible impact on protein structure and function. 
Results  
Exome sequencing was able to cover approximately 95% of the RefSeq coding 
regions of the genome, including +/-2bp on each side of each exon. This enabled us to 
identify the majority of variants in protein-coding regions, which currently are known to 
harbor 80-90% of known disease-causing variants [15]. To identify potential variants 
involved in DSD pathogenesis we used a DSD specific gene list to filter out variants 
identified by exome. For that, we developed a list of well annotated genes involved in 
sex determination and differentiation, as well as a secondary list of genes that are more 
loosely associated with sex development e.g. the OMIM (Online Medelian Inheritance of 
Man) description contains sex specific key words or data indicating involvement in sex 
development is available only from animal models (Table 1-4, 2-1).  
The variants identified by exome sequencing were classified into three 
categories: causative, likely causative and variants of unknown significance (VUS) 
following the recommendations of the American College of Medical Genetics [16]. 
Causative variants are defined as variants that have been previously reported with 
strong evidence of being pathogenic for a particular DSD phenotype. Likely causative 
variants are variants that have not been previously reported, but are identified as 
damaging in DSD genes directly related to the clinical phenotype. Variants of unknown 
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significance are variants with minor allele frequency of less than 1% that may or may 
not be the causative. This category excludes benign and likely benign variants. 
Summary depicted in Figure 2-1. 
We performed exome sequencing on a number of individuals diagnosed with 
DSD both with 46,XY and 46,XX karyotypes, a wide variety of clinical features and 
phenotypes of external genitalia (outlined in Tables 2-2; 2-3). In the 46,XY DSD subset 
of cases we were able to identify the genetic diagnosis in 35% of cases most of which 
had been worked up by candidate gene testing or chromosomal microarrays without a 
success (Table 2-4). The rate of diagnosis in 46,XX DSD subset of cases was much 
lower possibly due to smaller number of cases not explained in comparison with 46,XY 
DSD and smaller number of genes known to be associated with 46,XX DSD. The 
historic rate of undiagnosed cases for 46,XX DSD is only 10% whereas for 46,XY DSD 
it is 70%, indicating that more pathways exist in 46,XY DSD pathogenesis. 
We have identified a c.2522G>A (p.Arg841His) variant in the androgen receptor 
(AR) in the DSDEX94 patient with a working diagnosis of Complete Androgen 
Insensitivity Syndrome (CAIS). This variant was predicted to be damaging/pathogenic 
by all three in silico algorithms SIFT, PolyPhen and Condel. Using the androgen 
receptor database we were able to find a previous report of the same mutation 
indicating the pathogenicity of the variant [17]. The external appearance of this case 
was that of a normal female; however, testes were present inguinally producing enough 
testosterone to be in the male range. Identification of this variant had finally put to an 
end the genetic odyssey for this patient. 
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We identified several mutations in the mitogen activated protein kinase x3 1, E3 
ubiquitin protein ligase (MAP3K1) gene that has been emerging as one of the more 
common genes mutations in which result in 46,XY DSD. A previously reported 
c.1846G>A (p.Gly616Arg) pathogenic variant was identified in two of our cases who 
presented with two different phenotypes (a female with complete gonadal dysgenesis 
and a male with ovotesticular DSD and ambiguous genitalia respectively) [18]. These 
findings extend the spectrum of phenotypes associated with this variant. Additionally, 
we identified another three previously unreported mutations in MAP3K1 gene 
c.1016G>A (p.Arg339Gln); c.770C>T (p.Pro257Leu); c.1760T>A (p.Leu587His) in 3 
distinct patients DSDEX73; SN00458 and DSDEX118 respectively. All three variants 
were predicted  to be damaging by in silico tools. DSDEX73 presented as a 46,XY 
female with complete gonadal dysgenesis; hypoplastic uterus, fallopian tubes, bilateral 
streak gonads, primary amenorrhea and tall stature. SN00458 presented as a 46,XY 
individual with ambiguous genitalia; 2cm phallus, hypospadias, bifid scrotum, bilateral 
descended testes, no mullerian structures, no gonadal dysgenesis. These two 
mutations along with previously reported p.Gly616Arg variant indicate that the 
phenotypic spectrum of mutations in MAP3K1 is very wide.  
The DSDEX118 proband presented as a 46,XY female with complete gonadal 
dysgenesis and failure to enter puberty. The external genitalia were of a normal female. 
Internally this patient had small uterus, bilateral fallopian tubes and bilateral streak 
gonads. The proband also had one affected sister who had undergone bilateral inguinal 
hernia repair at an early age and one affected cousin with similar evaluations. The 
identified heterozygous variant c.1760T>A (p.Leu587His), was present in all affected 
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sisters with 46,XY karyotype and in unaffected aunt who had 46,XX karyotype indicating 
the 46,XY karyotype necessity for disease progression (Figures 2-2 and 2-3). 
We have generally been unlucky at finding pathogenic variants in 46,XX DSD 
cases with exome sequencing. However, we found a heterozygous c.274C>T 
(p.Arg92Trp) mutation in NR5A1 gene in one 46,XX male who did not have a copy of  
SRY gene. This variant was highly conserved, predicted damaging and was not seen in 
EVS, 1000G or ExAC. Mutations in NR5A1 have historically be associated with 46,XY 
sex reversal that is why at first this variant seemed unconvincing. Nevertheless, we 
were able to find two other families in collaboration with colleagues from France and 
United States that had an affected family member with similar phenotype as our case 
and who carried the exact p.Arg92Trp variant [19]. Functional studies show that this 
variant switches organ fate from ovary to testis through disruption of ovary-specific 
pathways that normally oppose testis development [19]. Several other groups have also 
identified p.Arg92Trp to be associated with 46,XX testicular and ovotesticular DSD [20-
22]. 
Discussion 
Exome sequencing allows identification of genetic cause in rare cases at much 
higher success rate when compared with other diagnostic techniques of comparable 
pricing. The use of gene lists as bioinformatics filters for exome sequencing allows for 
rapid identification of variants in known DSD genes in an individual sample. Moreover, 
when no causative variants are identified from one of these gene lists, one is able to 
analyze the complete exome sequencing data set to look for additional variants that 
might be disease causing. We prefer to use a trio analysis in which we sequence the 
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patient and both unaffected parents because each individual exome on average has 
20,000 variants compared to the reference sequence [15]. The majority of these 
variants are inherited, and by including parent’s sequences we can define de novo, 
heterozygous variants in addition to any homozygous or compound heterozygous 
variants.  
Exome sequencing allows for identification of variants in genes that have not 
been associated with DSD previously, such as the p.Arg92Trp mutation that we 
identified in NR5A1 gene in 46,XX males that is now associated with testicular DSD. 
One of the most important advantages of this approach is that all genes with any 
involvement in sex development can be analyzed concurrently, and new genes can be 
readily included in the analysis without needing to reconfigure the sequencing pipeline 
or re-sequence the samples. 
Conclusion 
Exome sequencing provides high throughput genetic diagnostic capability that 
has become the core of modern clinical genetics. In the field of disorders of sex 
development it has revolutionized the rate of successive genetic diagnosis. 
Nevertheless, exome sequencing is limited to only 1% of the entire genome which is a 
big limitation when trying to achieve a high diagnostic rate. Moreover, clinical exome 
sequencing relies on the information available about the gene such as function and 
molecular mechanism of action in order to be effective. Much of this information is 
currently unavailable. Thus, it is necessary to investigate molecular pathways, identify 
gene functions in order to be able to interpret variants identified by exome sequencing 
that are classified as “variants of unknown significance”. 
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Figures and Tables 
Table 2-1: Secondary gene list used for variant filtration in exome sequencing 
 
 
Gene ID Search Term Gene ID Search Term Gene ID Search Term
AKR1C2 'sexual' TRIM37 'testicular' DHCR7 hypospadias
AKR1D1 'steroid' TRPC6 'steroid' DISC1 bardet_biedl_syndrome
ATF3 hypospadias' TTC21B '+bardet +biedl' DNMT3L hypogonadism
AZF1 '+gonadal +dysgenesis' UGT2B17 'steroid' EFNB1 sex_reversal
BMP4 'hypospadias' UGT2B28 'steroid' EHD1 bardet_biedl_syndrome
BMP7 'hypospadias' WDPCP '+bardet +biedl' ELAVL4 sex_determination
BNC2 'hypospadias' WDR11 'hypogonadism EPHX1 disorder_of_sex_development
CCDC28B '+bardet +biedl' WWOX 'disorder of +sex +development' EPHX1 ovotesticular_dsd
CEP290 '+bardet +biedl' ACP5 steroid_synthesis ERCC3 sexual_development
CUL4B 'hypogonadism AHR steroid_receptors ERCC3 sexual_disorder
CYB5A 'disorder of +sex +development' ALMS1 hypogonadism ERCC5 hypogonadism
CYP11B1 'steroid' ARL13B bardet_biedl_syndrome ESR1 sexual_disorder
CYP11B1 '+Adrenal +Hyperplasia' ATM gonadal_dysgenesis ESR1 steroid_receptors
CYP11B2 'steroid' ATM sexual_disorder ESR2 hypospadias
DND1 'testicular' AUTS2 hypospadias ESR2 sexual_differentiation
ESR2 'hypospadias' BKMA1 hypogonadism ESR2 sexual_disorder
FOXF2 'disorder of +sex +development' BKMA1 sexual_differentiation ESR2 steroid_receptors
FSHR 'hypogonadism BMPR1A sexual_development ESRRA steroid_synthesis
GHRHR '+pituitary +hormone deficiency' BMPR1A sexual_differentiation F9 sexual_disorder
HOXA4 'hypospadias' BRCC3 hypogonadism F9 steroid_synthesis
HOXB6 'hypospadias' CAPN5 sex_determination FANCA hypogonadism
HS6ST1 'hypogonadism CCDC28B bardet_biedl_syndrome FANCG hypogonadism
KCNJ5 '+Adrenal +Hyperplasia' CEP290 bardet_biedl_syndrome FANCM hypogonadism
KIF7 '+bardet +biedl' CEP41 ambiguous_genitalia FEM1C sex_determination
KISS1 'hypogonadism CGNL1 hypogonadism FEM1C sexual_development
LHB 'hypogonadism CITED2 sex_determination FGF10 hypospadias
LHFPL5 'hypospadias' CITED2 sex_reversal FGFR3 disorder_of_sex_development
LHX4 '+pituitary +hormone deficiency' CLCN4 sexual_differentiation FGFR3 ovotesticular_dsd
LZTFL1 '+bardet +biedl' CLTCL1 hypospadias FKBP4 hypospadias
MID1 'hypospadias' COL2A1 disorder_of_sex_development FLNA sexual_differentiation
MKS1 '+bardet +biedl' COL2A1 ovotesticular_dsd FLNA sexual_disorder
MYO1E 'steroid' COQ2 steroid_synthesis FREM2 ambiguous_genitalia
NELF 'hypogonadism COX14 Adrenal_Hyperplasia FSHB hypogonadism
NMT2 'hypogonadism CRH sexual_disorder FSHR hypogonadism
NPHS2 'steroid' CSF2RA sexual_disorder G6PC2 bardet_biedl_syndrome
OTX2 '+pituitary +hormone deficiency' CUL4B hypogonadism GAL hypogonadism
PDE11A 'testicular' CUL4B hypospadias GATA5 hypospadias
PDE8B '+Adrenal +Hyperplasia' CUL4B steroid_receptors GHRHR pituitary_hormone_deficiency
POLR3A 'hypogonadism CYP11B1 Adrenal_Hyperplasia GLYCTK pituitary_hormone_deficiency
POU1F1 '+pituitary +hormone deficiency' CYP11B2 steroid_synthesis GNAS Adrenal_Hyperplasia
PSMC3IP '+gonadal +dysgenesis' CYP19A1 disorder_of_sex_development GPC3 ambiguous_genitalia
RET '+bardet +biedl' CYP19A1 hypogonadism HAMP hypogonadism
RPGRIP1L '+bardet +biedl' CYP19A1 ovotesticular_disorder_of_sex_deve HBA1 hypospadias
SDCCAG8 '+bardet +biedl' CYP19A1 sexual_disorder HBA2 ambiguous_genitalia
SDHB '+Adrenal +Hyperplasia' CYP19A1 testicular_disorder_of_sex_developmHBA2 hypospadias
SNORD116 'hypogonadism CYP7B1 steroid_receptors HBB disorder_of_sex_development
SOX2 'hypogonadism DCAF17 hypogonadism HBB ovotesticular_dsd
TDRD7 'hypospadias' DGKK hypospadias HBB sexual_differentiation
TMEM67 '+bardet +biedl' DHCR24 steroid_synthesis HES1 sex_determination
TRIM37 'testicular' DHCR7 ambiguous_genitalia HEXB sexual_disorder
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Table 2-1: continued 
 
 
 
 
Gene ID Search Term Gene ID Search Term Gene ID Search Term
HFE2 hypogonadism MSC sex_determination SLC6A4 ovotesticular_dsd
HOXA13 hypospadias MTCP1 hypogonadism SLC9A3R2 sex_determination
HOXD10 bardet_biedl_syndrome MTHFR disorder_of_sex_development SMPD2 pituitary_hormone_deficiency
HSD11B2 Adrenal_Hyperplasia MTHFR ovotesticular_dsd SMPD3 pituitary_hormone_deficiency
HTR2A sexual_disorder MTMR1 sexual_development SNORD116-1 hypogonadism
HTR3A sexual_disorder MTMR1 sexual_disorder SOD2 hypogonadism
IGF1R sex_determination NCOA2 steroid_receptors SOX10 sex_reversal
IGF1R sexual_differentiation NCOA4 steroid_receptors SOX10 sexual_development
IGFALS sexual_development NDN hypogonadism SOX10 sexual_disorder
INHBA hypogonadism NDUFS4 hypospadias SOX2 hypogonadism
INHBB hypogonadism NEDD4 steroid_receptors SOX2 hypospadias
INSR sex_determination NELF hypogonadism SPO11 gonadal_dysgenesis
INSR sexual_differentiation NKAIN2 hypogonadism SRD5A1 hypospadias
INSRR sex_determination NMT2 hypogonadism SRD5A3 sexual_disorder
INSRR sexual_differentiation NOS1 sexual_disorder STAT5B sexual_development
IRF6 hypospadias NPC1 steroid_synthesis STS hypogonadism
ITGB3 disorder_of_sex_development NR2C1 steroid_receptors TAB2 steroid_receptors
ITGB3 ovotesticular_dsd NR2E3 bardet_biedl_syndrome TDRD7 hypospadias
KCNJ5 Adrenal_Hyperplasia NR3C1 Adrenal_Hyperplasia TFR2 hypogonadism
KDM5D sex_determination NR3C1 ambiguous_genitalia THRB disorder_of_sex_development
KDM5D sexual_differentiation NR3C1 steroid_receptors THRB ovotesticular_dsd
KISS1 hypogonadism NR4A1 sexual_differentiation TMEM67 bardet_biedl_syndrome
KRT86 sexual_disorder NR4A1 steroid_receptors TMEM70 hypospadias
LATS1 hypogonadism OTX2 pituitary_hormone_deficiency TNXB Adrenal_Hyperplasia
LHB disorder_of_sex_development PEX2 sexual_disorder TP63 hypogonadism
LHB hypogonadism PGR steroid_receptors TPH2 sexual_disorder
LHB ovotesticular_dsd PHF6 hypogonadism TPI1 sexual_disorder
LHB sexual_development PKD1 Adrenal_Hyperplasia TRA2A sex_determination
LHB testicular_dsd PLCB3 bardet_biedl_syndrome TRA2A sexual_differentiation
LHX4 pituitary_hormone_deficiency PLLP bardet_biedl_syndrome TRNL1 hypogonadism
LHX9 gonadal_dysgenesis POLG hypogonadism TTR sexual_disorder
LHX9 sex_determination POLR3A hypogonadism TUB bardet_biedl_syndrome
LIG4 hypogonadism POLR3B hypogonadism VANGL2 bardet_biedl_syndrome
LIPE hypogonadism POU1F1 pituitary_hormone_deficiency WDPCP bardet_biedl_syndrome
LMNA hypogonadism RAB3GAP2 hypogonadism XG sex_reversal
MAGEB1 sex_determination RCN2 bardet_biedl_syndrome XG sexual_development
MAGEB2 sex_reversal RET disorder_of_sex_development ZDHHC21 steroid_receptors
MAGEL2 hypogonadism RET ovotesticular_dsd ZDHHC7 steroid_receptors
MAOA sexual_disorder RFXAP pituitary_hormone_deficiency ZEB2 hypospadias
MBTPS2 hypospadias RPL35A hypospadias ZFX gonadal_dysgenesis
MC4R hypogonadism RPS4X gonadal_dysgenesis ZFX hypogonadism
MC4R sexual_development RPS4Y1 gonadal_dysgenesis ZFX sex_determination
MC4R sexual_disorder SALL1 hypospadias ZFY sex_determination
MEF2B steroid_receptors SAT1 sex_reversal
MEN1 Adrenal_Hyperplasia SDCCAG8 bardet_biedl_syndrome
MEN1 disorder_of_sex_development SHOX gonadal_dysgenesis
MEN1 ovotesticular_dsd SIL1 hypogonadism
MID1 hypospadias SLC29A3 hypogonadism
MKS1 bardet_biedl_syndrome SLC6A4 disorder_of_sex_development
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Table 2-2: List of DSD patients with corresponding phenotypes and clinical features that 
have undergone exome sequencing. 
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Table 2-2: continued 
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Table 2-3: List of 46,XX DSD patients with corresponding phenotypes and clinical 
features that have undergone exome sequencing 
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Table 2-4: DSD patients with 46,XY karyotype with corresponding exome result 
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Table 2-5: DSD patients with 46,XX karyotype with corresponding exome result. 
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Figure 2-1: Classification of variants identified by exome sequencing into categories. 
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Figure 2-2: Pedigree of a familial case of 46,XY complete gonadal dysgenesis 
 
Arrow indicates the proband. 
 
 
Figure 2-3: Sanger sequencing of family members showed that all affected individuals 
with 46,XY karyotype were heterozygous for the identified mutation. 
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Chapter 3 
 
Identification of Novel Candidate Genes for  
46,XY Disorders of Sex Development (DSD) using  
C57BL/6J-YPOS Mouse Model 
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Abstract 
Disorders of Sex Development (DSD) have an estimated frequency of 0.5-1% of 
live births encompassing a variety of urogenital abnormalities ranging from mild 
hypospadias to complete sex reversal. In order to identify the underlying genetic 
etiology in a subset of DSD cases with 46,XY karyotype, we performed exome 
sequencing and were able to identify the causative genetic variant in 35% of cases. 
While the genetic etiology was not ascertained in more than half of the cases, a large 
number of variants of unknown clinical significance (VUS) were identified in those 
exomes. To investigate the relevance of these VUS in regards to the patient’s 
phenotype, we utilized a mouse model in which the presence of a Y chromosome from 
the poschiavinus strain (YPOS) on a C57BL/6J (B6) background results in XY 
undervirilization and sex reversal, a phenotype characteristic to 46,XY DSD cases. We 
hypothesized that abnormal gonadal expression of specific genes in B6-YPOS males 
during embryonic development would correlate with genes in which VUS were identified 
in the exomes of 46,XY DSD patients. We isolated gonadal tissue from wild type (WT) 
B6 and undervirilized B6-YPOS males at embryonic day 11.5 and performed RNA 
sequencing to assess differential gene expression. The list of differentially expressed 
genes from the mouse model was filtered using the list of human genes containing VUS 
in 46,XY DSD cases to identify overlap. This identified 15 novel candidate genes with 
mutations in 46,XY DSD cases that may be associated with disease pathogenesis. We 
also show that all of the candidate genes were under direct regulation of the well-known 
sex determination gene Sox9. 
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Introduction 
Human sex development is dictated by the inheritance of either an X or Y 
chromosome from parents to offspring. The male sex determination starts with the 
expression of a transcription factor SRY on Y chromosome in bipotential gonads 
initiating testicular organogenesis [1]. In the absence of the Y chromosome, female 
specific pathways are initiated for proper ovarian development. Secretion of testicular or 
ovarian hormones further differentiate body into typical male or female structures, 
including both internal and external genitalia. Anomalies in hormonal exposure and/or 
gene mutations disrupting sex development pathways lead to Disorders of Sex 
Development (DSD), defined as “congenital conditions in which development of 
chromosomal, gonadal, or anatomic sex is atypical” [2]. The umbrella term DSD 
encompasses conditions ranging from mild hypospadias (abnormal location of the 
meatus) to discrepancy between sex chromosomes and external genital phenotype 
(formerly known as sex reversal, either complete or with ambiguous genitalia). DSDs 
are estimated to affect 0.5-1% of the population. The birth of a child with a DSD is 
potentially quite stressful for families, bringing uncertainty in regards to future 
psychosexual development and clinical management [2-4].  
At present a specific molecular diagnosis is identified at variable rates in different 
DSD subtypes. The majority (80-90%) of isolated 46,XX testicular DSD are explained by 
SRY translocations [5]. More recently a single nucleotide variant in NR5A1 gene 
resulting in p.Arg92Trp amino acid change has been associated with 46,XX testicular 
(and ovotesticular) DSD [6, 7]. Approximately 50% of ovotesticular DSD are explained 
by SRY translocations, sex chromosome mosaicism and partial translocations [8]. 
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Among 46,XY DSD cases 15% are due to SRY defects, 13% due to NR5A1 defects and 
several due to other rare mutations (SOX9, NR0B1, FGFR,…). More recent data 
suggests that an additional 10-18% of 46,XY DSD cases may be explained by 
mutations in MAP3K1 gene. Nevertheless, collectively the genetic etiology is still not 
identified in greater than 50% of DSD patients, suggesting the existence of a number of 
unknown sex determining genes. 
Next-generation sequencing has now become instrumental in DSD diagnosis, 
including clinical exome sequencing and gene panels [9-11], with high diagnostic rates 
reported for known DSD genes. In a cohort of 46,XY DSD patients, we were able to 
establish a diagnosis in approximately 1/3 of cases [12], similar to rates for other rare 
disorders [13, 14]. Another 15% of the exomes in the cohort contained variants in 
known DSD genes that couldn’t be validated but were reported to the referring clinicians 
to orient further endocrine or imaging testing toward a definitive diagnosis. Half of the 
cases from our cohort remained undiagnosed but contained hundreds of variants of 
unknown significance (VUS) that provide opportunity for research into new etiology of 
DSD. Here, we utilize an animal model resembling the phenotype of human 46,XY DSD 
patients [15, 16] to identify the genetic diagnosis in exome-negative cases (no 
pathogenic variant identified). We present a novel method that allows for identification of 
candidate genes involved in 46,XY DSD pathogenesis. 
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Results 
Exome-negative 46,XY DSD cases 
As previously described, we have performed exome sequencing on a cohort of 
40 individuals diagnosed with 46,XY DSD [12]. To identify the disease-causing 
mutations a DSD-specific gene list, published elsewhere [9], was used for variant 
filtration.  Exome sequencing was not able to identify the genetic diagnosis in 50% of 
cases. To address this issue, we compiled a cohort of 32 exome-negative DSD cases 
with 46,XY karyotype for further investigation (Table 3-1) (this new cohort includes 21 
unresolved cases from [12] and additional 11 exome-negative cases enrolled since). As 
evident from Table 3-1, the range of associated clinical features was wide, which is a 
typical characteristic of DSD presentation. Patients could be grouped into four 
categories based on the appearance of the external genitalia and gonadal development: 
46,XY women with complete gonadal dysgenesis (CGD), when gonadal phenotype had 
been ascertained by the clinical team; 46,XY Females; 46,XY with ambiguous genitalia 
(and unknown sex of rearing at the time of enrollment); 46,XY males, with 
hypogonadism. 
C57BL/6J-Y poschiavinus mice as a model for 46,XY DSD 
 In exome-negative cases, where no pathogenic variant was found, we identified 
many variants of unknown significance outside of the DSD clinical gene list. To 
investigate the relevance of these VUS in regards to patients’ phenotype, we utilized a 
powerful mouse model used for studying undervirilization in human 46,XY individuals. In 
this model, the presence of a Y chromosome originating from a M. domesticus 
poschiavinus strain (YPOS) on a C57BL/6J (B6) background (B6-YPOS), an inbred 
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laboratory strain that normally carries a M. musculus Y chromosome, results in 
disrupted testicular development and sex reversal [17].  
This inherited phenomenon has been extensively studied in the B6-YPOS males. 
The failure to develop testes stems from the inability of the SryPOS gene to initiate 
normal testicular development when B6 autosomal and/or X-linked factors are present. 
Virtually all B6-YPOS animals develop some ovarian tissue; half develop exclusively 
ovarian tissue, classified as completely sex-reversed, and the remainder develop both 
ovarian and testicular tissue, classified as partially sex-reversed (gonad morphology 
shown in Figure 3-1A). We have previously identified a 1.5-Mb congenic region on 
chromosome 11 that confers 80% protection from B6-YPOS sex reversal in the 
heterozygous state (B6-110h-YPOS) and complete protection in the homozygous state 
(B6-110H-YPOS) [18]. This protective region allows for continual maintenance of 
subfertile Poschiavinus male mice as a breeding colony, with an option of generating 
unprotected B6-YPOS males by mating heterozygous B6-110h-YPOS males with wild type 
(WT) B6 females. 
In the embryonic mouse gonad, Sry is normally expressed in a dynamic wave 
(central to distal) between E10.5 and E12.5 in the XY genital ridge with peak Sry 
expression occurring in normal XY B6 genital ridges at ~E11.5, i.e., at the 16-18 tail 
somites stage of development [19]. In contrast, expression of the SryPOS gene peaks 10 
to 14 hours later in the genital ridges of B6-YPOS fetuses [20]. We hypothesized that 
abnormal gonadal expression of specific genes in B6-YPOS males, after the surge of Sry 
during gonadal development, would correlate with VUS in genes of 46,XY DSD patients 
identified through exome sequencing. 
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Gene expression differences between B6-YB6 and of B6-YPOS males 
Since all of the 46,XY DSD patients in the exome-negative cohort carried a 
functional SRY gene it was important to perform gene expression analysis in the animal 
model after the peak of Sry expression for optimal comparability. To achieve this, 
gonadal tissue from WT B6-YB6 and undervirilized B6-YPOS males at embryonic day 
E11.5, specifically at 21 tail somites (ts) (a time point when the surge of Sry gene was 
complete in both B6-YB6/B6-YPOS males) was collected to perform RNA sequencing for 
assessment of differential gene expression. To obtain sufficient RNA for sequencing 
and to minimize the impact of gonad-to-gonad variation, dissected embryonic gonads of 
identical genotypes were pooled together for a single RNA extraction and subsequent 
sequencing.  
Using this method, we identified 515 genes that were differentially expressed 
between B6-YB6/B6-YPOS males with a fold change greater than 1.5. Out of these 515 
genes, 308 were underexpressed and 207 were overexpressed in B6-YPOS males 
(Figure 3-2) (Supplemental Table 3-S1). To validate the integrity of the method, we 
verified which of the genes in our DSD gene list used for exome variant filtering were 
present in the B6-YB6/B6-YPOS differentially expressed gene list. The comparison of the 
two lists revealed that 21 genes were in common - 15 underexpressed and 6 
overexpressed (Supplemental Table 3-S1). In our previous cohort [12], out of these 21 
genes, 3 (HSD17B3, STAR, FGFR2) contained a previously identified pathogenic 
variant by exome sequencing explaining a total of 5 cases and 2 (DHH, MAMLD1) 
contained a convincing VUS. Cumulatively, these findings indicate the ability of the 
method to identify genes important in sex development. 
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Filtering of VUS in 46,XY DSD cases using the B6-YPOS gene list 
On average exome sequencing identifies ~ 21,000 variants per single case [13]. 
Since DSDs are rare conditions, all variants identified in exome with a minor allele 
frequency (MAF) of more than 1% in the population were excluded. The variants 
remaining after the MAF cutoff, were classified as variants of unknown significance. The 
gene list generated via expression studies in B6-YB6/B6-YPOS mice, consisting of 515 
genes, was filtered against the list of VUS-containing human genes identified by exome 
sequencing. The comparison of two lists identified 305 (189 underexpressed and 116 
overexpressed in B6-YPOS) genes that were both differentially expressed in B6-YPOS 
males and contained a VUS in our exome-negative 46,XY DSD cohort (Figure 3-2).  
All these genes are known to be expressed in the developing gonad at the time 
of sex determination. In order to increase the probability of identifying relevant 
candidate genes involved in 46,XY DSD pathogenesis, we queried if the genes from the 
mouse model were involved in any known biological processes. Gene Ontology 
Consortium (GOC) [21] enrichment analysis confirmed that genes underexpressed in 
B6-YPOS males were indeed enriched in biological processes known to control 
multicellular organism and anatomical structure development, including male 
reproductive development (Table 3-2). Understanding the relevance of the genes that 
were overexpressed in B6-YPOS males was less straightforward. Those were enriched in 
only two biological processes: response to extracellular stimulus and epithelial cell 
differentiation. Both of these categories had a high P-value indicating that many genes 
in the overexpressed category are not associated with any known biological processes 
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at this time. In addition, all of the pathogenic variants identified in our previous 46,XY 
DSD cohort [12] were in the underexpressed category of genes, indicating that they 
need to be expressed at higher levels in the developing gonad for proper testicular 
formation.  
Based on these findings, we decided to focus on variants identified in the 189 
genes underexpressed in B6-YPOS males whose higher expression in WT males 
correlates with normal male sex development. To choose a fold change cutoff, we 
looked at fold change differences in expression between B6-YB6 and B6-YPOS males for 
genes present in our primary clinical gene list (Supplemental Figure 3-S1). We found 
that more genes have an expression that is 2 fold higher in WT males compared to B6-
YPOS males. To make the analysis more stringent and increase the confidence of 
identifying true candidate genes involved in male sex development we therefore 
increased the fold change cutoff in expression between the B6-YB6 and B6-YPOS males 
from 1.5 to 2. This change decreased the number of genes from 189 to 53. Additional, 
filtering was performed based on variant frequency, amino acid conservation, number of 
variants, in silico predictions for pathogenicity, availability of the literature, and gonadal 
cell-specific expressivity using GenitoUrinary Developmental Molecular Anatomy Project 
data (GUDMAP) [22].  
Using the above mentioned filtering criteria, we identified 15 novel candidate sex 
developmental genes variants that may be involved in 46,XY DSD pathogenesis. The 
list of VUS identified in the 46,XY cohort is shown in Table 3-3. The relative expressions 
of these genes in B6-YB6, B6-YPOS and WT female are shown in Figure 3-3. The 
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expression changes of all 15 genes were confirmed by quantitative real time PCR 
(Supplemental Figure 3-S2). 
Novel candidate genes are under Sox9 regulation 
Although the time point chosen for our gene expression analysis was such that 
the Sry gene expression was similar between in B6-YB6 and B6-YPOS males, the 
downstream target of Sry, Sox9, was significantly higher in WT B6-YB6 males 
(Supplemental Figure 3-S3). In order to identify if any of our candidate genes fell under 
the direct regulation of Sox9, we used a mouse model where Sox9 expression is 
suppressed in Sertoli cells using Amh-Cre Sox9flox/flox mice [23]. By E13.5, Sox9 
protein is completely absent (Figure 3-1B) and these mice show postnatal fertility 
defects. This model allows the examination of Sox9 loss in an intact Sertoli cell 
environment. Earlier Sox9 knock out models result in complete sex reversal (XY 
ovaries) [24, 25] or embryonic lethality [26]; neither situation sheds light on Sox9 target 
genes during sex determination.  
The profiles of gonadal gene expression from GUDMAP reveal that almost all 
cases, the patterns of gene expression are similar to bona fide target genes such as 
Amh and Ptgds [27, 28]. The target gene expression is higher in the male supporting 
cells (Sertoli) than in the female supporting cells (granulosa) (Supplementary figure 3-
S4). 
We identified that all 15 genes were also underexpressed in mice with 
suppressed Sox9 expression, suggesting that the novel candidate genes for 46,XY DSD 
are downstream targets of Sox9, in the sex-determining pathway. This in turn 
strengthens our findings that mutations in these candidate genes such as the ones 
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we’ve identified in our 46,XY DSD cases (Table 3-3) may be responsible for the 
patient’s phenotype. 
 
Discussion 
The use of the undervirilized B6-YPOS mice as a model for 46,XY DSD in humans 
provides valuable screening information towards the identification of novel genes 
involved in male sex development, mutations in which could lead to anomalies of genital 
development in 46,XY patients with DSD. All these genes are expressed in the 
developing mouse gonad at the relevant time for sex determination and are all under 
the control of major male sex determination Sox9.  
Mutations in the novel candidate genes identified via the YPOS mouse model are 
likely to be causative. For example, one of the candidate genes Adamts16 (A Disintegrin 
And Metalloproteinase with Thrombospondin Type 1 Motif, 16) has been shown to be 
co-expressed with the known DSD gene Wt1 in embryonic gonads, adult testes and 
spermatids [17]. Moreover, targeted disruption of Adamts16 in rats results in 
cryptorchidism and sterility [29]. In our exome-negative DSD cohort, we identified three 
heterozygous variants in this gene (Table 3-3). Patients DSDEX53 and DSDEX02, both 
46,XY females with complete gonadal dysgenesis, had a missense variant leading to 
amino acid change at positions p.Val734Ile and p.Arg100Trp respectively. These 
changes were located in propeptide and Cysteine-rich domains of the Adamts16 protein 
and may prevent expression or proper folding of the protein. The third missense variant 
(p.Phe469Val) in patient DSDEX43 (46,XY, with ambiguous genitalia) was located in 
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the peptidase domain of the protein and predicted damaging by in silico tools 
suggesting a possible impairment of the enzymatic function of Adamts16. 
We have also identified two rare variants (p.Ala496Thr; p.Ala1202Gly) in the 
FBLN2 gene in two exome-negative cases with different phenotypes: 46,XY Female 
with inguinal testes/enlarged clitoris and 46,XY Male with hypospadias. Additional rare 
FBLN2 variants were present in six other unrelated cases with previously identified 
genetic diagnosis (with a pathogenic variants identified in known DSD genes).This 
suggest that variants in FBLN2 are overrepresented in DSD population and may act as 
modifiers of the phenotype. We show that the Fbln2 protein is expressed in a sexually 
dimorphic pattern in the developing gonad by immunohistochemical staining 
(Supplemental Figure 3-S5): at E12.5 WT B6 females have virtually no expression in 
the developing ovaries, whereas WT B6 males have very high expression in developing 
testes suggesting an important role of Fbln2 in gonad development. FBLN2 has been 
proposed as a candidate gene for 46, XY DSD in an unpublished meeting abstract (K. 
MacElreavey, personal communication).  
We identified a single variant, predicted to be damaging by in silico tools, in the 
SPRY4 gene in a 46,XY male patient (SN00441-P) with hypogonadism. SPRY4 is one 
of the genes in which variants have been found in a cohort of patients presenting with 
Hypogonadotropic Hypogonadism with or without anosmia (HH17, OMIM #615266) [30]. 
These genes are believed to be functioning in an oligogenic model, with variants in 
several genes possibly needed for phenotypic expression. Variants in SPRY4 have 
been found in association with variants in FGFR1 (HH2, OMIM #147950) and DUSP6  
(HH19, OMIM #615269). We didn’t identify FGFR1 or DUSP6 variants in the exome of 
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patient SN00441-P (which would have been diagnostic for this patient). However 
DUSP6 is present in the differentially expressed gene list (underexpressed in B6-YPOS 
with a fold-change of 1.7) and another gene coding for a dual-specificity phosphatase, 
DUSP15, is in our final candidate gene list, with underexpression in YPOS (fold change 
>2) and a VUS in one patient.  
 
Conclusion: 
Exome sequencing provides high throughput genetic diagnostic capability that 
has become the core of modern clinical genetics. However, many variants identified by 
whole exome sequencing are uninterpretable clinically. The C57/BL6J-YPos model 
allows to improve the interpretive gap by correlating human sequence variants and RNA 
sequencing variations. This approach allowed the identification of 15 novel candidate 
genes for human DSD. 
 
Materials and Methods 
Exome sequencing and analysis 
Exome sequencing (ES) covers approximately 95% of the RefSeq coding regions 
of the genome, including +/-2bp on each side of each exon, and thus identifies the 
majority of variants in protein-coding regions, which currently harbor 80-90% of known 
disease-causing variants [31]. 
DNA was isolated from peripheral blood using Gentra Puregene Blood Kit 
(Qiagen, Germantown, MD, USA) or saliva collected using ORAgene Discover ORG-
500 (DNAgenoteck Ottawa, ON, Canada). Sequencing libraries and exome capture was 
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done for each sample following manufacturer’s protocols for SureSelect All Exon 50 Mb 
capture kit (Agilent Technologies) and Nextera Rapid Capture (Illumina, San Diego, CA 
USA). Sequencing was performed on an Illumina HiSeq 2000 or HiSeq2500 as 50bp or 
100bp paired-end run at the UCLA Clinical Genomics Center.  
The sequence reads FASTQ files were aligned to the human reference genome 
(GRCh37/hg19 Feb. 2009 assembly) using BWA (Burrows-Wheeler Alignment Tool) 
[32] . The output BAM file were sorted, merged, and PCR duplicates removed using 
Picard. INDEL (insertions and deletions) realignment and recalibration was performed 
using Genome Analysis Tool Kit (GATK) from the Broad Institute. Both single-nucleotide 
variants (SNVs) and small INDELs were called within the Ensembl coding exonic 
intervals +/-2bp using GATK’s Unified Genotyper and recalibrated and filtered using 
GATK variant-quality score recalibration and variant filtration tools. All high-quality 
variants were annotated using VarSeq Variant Annotation, Filtering and Interpretation 
Software (Golden Helix, Inc., Bozeman, MT, www.goldenhelix.com). All variants were 
filtered by minor allele frequency (MAF) of <1% and intersected with the DSD gene list 
to identify mutations in known DSD genes. The list is comprised of a primary gene list of 
well annotated genes involved in sex determination and differentiation [9], as well as a 
secondary list of genes that are more loosely associated with sex development: e.g. 
their OMIM (Online Mendelian Inheritance of Man) description contains sex 
development key words or data is available only from animal models.  
The variants identified by exome sequencing were classified into three 
categories: causative, likely causative and variants of unknown significance (VUS) 
following the recommendations of the American College of Medical Genetics [33]. To 
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assess previously unreported missense variants we used two in silico algorithms SIFT 
[34] and  PolyPhen [35]. These algorithms predict the likelihood that a given missense 
variant is pathogenic, based on conservation of the amino acid across species, the 
physical characteristics of the altered amino acid and the possible impact on protein 
structure and function. All variants with low quality scores were validated by Sanger 
sequencing. 
 
Animal care and dissections 
All animals were housed at the UCLA Animal Care Facility following the 
guidelines of the University of California, Los Angeles (UCLA) Division of Laboratory 
Animal Medicine. All experiments were approved by the Institutional Animal Care and 
Research Committees of UCLA. Wild type C57BL/6J males and females used for 
breeding and experiments were purchased from the Jackson Laboratory (Bar Harbor, 
ME, USA) that is fully accredited by the American Association for Accreditation of 
Laboratory Animal Care.  
Congenic mice protected from sex reversal were used to generate B6-YPOS 
males [15]. Overnight mating was performed using either wild type (WT) B6 or B6-110h-
YPOS (protected from sex reversal) males and three 8-week-old WT B6 female mice 
each. The morning after the overnight mating the WT B6 females were checked for 
presence of a vaginal plug and separated into a new cage. At E11.5 of gestation, 
pregnant females were sacrificed. Embryos were removed from and placed in PBS for 
the duration of dissections that were performed under light microscope. Both right and 
left embryonic gonads were separated from the mesonephros and placed in RNA 
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stabilizing solution (RNAlater, Ambion, Life Technologies). DNA was extracted from the 
rest of the embryos’ bodies for genotyping PCRs. Chromosomal sex was determined 
using a single primer pair that detects the X-linked Smc-x gene (330 bp) and the Y-
linked Smc-y gene (301 bp) (Forward: 5´CCGCTGCCAAATTCTTTGG3´; Reverse: 
5´TGAAGCTTTTGGCTTTGAG3´). The presence of the YPOS chromosome was 
determined by a single nucleotide polymorphism (SNP) between YB6 and YPOS Sry gene 
using the primer sets 5´TGAATGCATTTATGGTGTGGTC3´; 
5´AGCTTTGCTGGTTTTTGGAGTA3´. Immomix Red 2x (Bioline, London) was used for 
PCR amplification following manufacturer’s guidelines with annealing temperature at 
60˚C and resolved by electrophoresis on a 2% agarose gel. Presence or absence of the 
110h protective region in B6-YPOS males was checked by Sanger sequencing of two 
regions 11-10 and 11-11 containing SNP rs27019103 
(5´AAAGTGTGCTTCCCAGGAGA3´; 5´CCTCTCCCTCAACCCCTAAG3´) and SNP 
rs28240850 (5´CCACAGCTGGAGGTAGGGTA3´; 5´CCTAAGATGCCATGGGAAGA3´) 
respectively [15].  
Total RNA was isolated from combined embryonic gonadal tissue (50-70 gonads 
per group) using Qiagen RNeasy Plus Mini Kit (Qiagen) following manufacturer’s 
guidelines. RNA quality was assessed by Agilent 2100 Bioanalyzer (Agilent 
Technologies) following standard protocols at the UCLA Genotyping and Sequencing 
Core. All samples were required to have RNA integrity scores (RIN) greater than 7.  
RNA sequencing and expression analysis 
Good quality RNA from each sample was submitted to UCLA Neuroscience 
Genomic Core (UNGC) for library preparation and sequencing. Library preparation was 
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performed using TruSeq Stranded Total RNA (Illumina) kit with Poly-A selection 
following manufactures guidelines. Libraries were multiplexed and sequenced across 2 
lanes using HiSeq 2500 (Illumina) with 69 bp paired-end run on a rapid flowcell 
generating 150M reads per lane. Four samples were multiplexed and sequenced over 
two rapid lanes with each sample receiving approximately 75 million reads with >85% 
map rate.  
The generated sequencing reads were aligned to the mouse genome, versions 
mm9 and mm10 with TopHat v2.0.2 [36] and STAR [37] aligner respectively. Transcript 
abundance was assessed by Cufflinks (v2.1.1) [38], using a GTF file based on Ensembl 
mouse NCBI37. Differential expression analysis was based on fold change differences 
greater than 1.5 between the groups being compared.  
Differentially expressed genes were split into two categories: underexpressed 
and overexpressed in B6-YPOS males. Both categories were separately subjected to 
pathway enrichment analysis using Gene Ontology Consortium [39] and PANTHER 
classification system [40]. 
 
Quantitative PCR 
 Reverse transcription of RNA to cDNA was performed using Tetro cDNA 
Synthesis Kit (Bioline, Taunton, MA USA) following manufacturer’s protocol with 1µg of 
total RNA as template. The RNA samples used for validation were from the same batch 
of RNA used for RNA sequencing above. The primer sequences used are detailed in 
(Supplemental Table 3-S2). Primers were designed using autoprime software 
(www.autoprime.de) and spanned exon-exon junctions for optimal RNA quantification. 
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cDNA was quantified using QuBit HS (Invitrogen) for double stranded DNA and a total 
of 3ng of cDNA was used per sample for amplification. qPCR was carried out in 
duplicate utilizing Syber Green-based SensiMix SYBR No-Rox Kit (Bioline). Reaction 
conditions were as follows: 95ºC for 10 min, then 40 cycles of 95ºC for 15 sec, 60-64ºC 
(see Table S2), and 72ºC for 15 sec. 
 Immunohistochemistry 
 Fbln2 expression in embryonic gonads at E12.5 was assessed using 
immunohistochemistry (IHC) following the experimental design of Wilhelm et al. [41], 
using the Fbln2 rabbit polyclonal, sc-30176 (Santa Cruz Biotechnology) antibody. Topro 
(Invitrogen) was used to counterstain nuclei. All images were taken on a Zeiss LSM 510 
Meta confocal microscope.  
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Figures and Tables: 
Table 3-1: Exome-negative cohort of 46,XY DSD cases 
Patient ID DSD Category Clinical Features 
RDSD002 46,XY Female, CGD – 
RDSD003 46,XY Female, PGD No uterus, Fallopian tubes 
present, short vagina, very low T 
and undetectable Estradiol, 
gonads not found 
RDSD006 46,XY Female Amelia (missing limbs) 
RDSD007 46,XY Female, GD Adrenal rests 
RDSD010 46,XY Female Clitoromegaly 
RDSD011 46,XY Female  Short stature 
RDSD012 46,XY Female  Kidney disease, possible Denys-
Drash syndrome 
RDSD013 46,XY Female, CGD Normal uterus and Fallopian 
tubes, streak gonads  
RDSD017 46,XY Female, GD – 
RDSD018 46,XY Ambiguous Genitalia Partial fusion of labioscrotal 
folds, small phallus, penoscrotal 
hypospadias 
RDSD020 46,XY Ambiguous Genitalia Developmental delay, agenesis 
of corpus callosum  
RDSD021 46,XY Ambiguous Genitalia Adrenal Hypoplasia Congenita, 
other dysmorphic features 
RDSD022 46,XY Ambiguous Genitalia Microcephaly, intestinal 
dysmotility, optic nerve 
hypoplasia 
RDSD025 46,XY Male, 
Micropenis/Cryptochidism 
Severe growth and 
developmental retardation, 
testes not seen by ultrasound 
CDSD029 46,XY Male, Hypospadias – 
CDSD030 46,XY Female  Large clitoris; no uterus or 
vaginal opening; inguinal testes 
CDSD031 46,XY Ambiguous Genitalia, CGD Abdominal gonads with no 
oocytes, no seminiferous 
tubules; no clitoromegaly; 
posterior fusion of labia; 
urogenital sinus 
CDSD032 46,XY Female Inguinal testes w/ immature 
seminiferous tubules; no uterus 
or Fallopian tubes; deafness; 
impaired cognition 
CDSD034 46,XY Ambiguous Genitalia Undescended testes, bifid 
scrotum, hypospadias 
CDSD036 46,XY Ambiguous Genitalia Bilateral descended testes, 
midshaft hypospadias, chordee 
CDSD039 46,XY Male, Micropenis No uterus or ovaries per 
ultrasound, ambiguous genitalia, 
under virilization 
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RDSD041 46,XY Female  Complete Androgen Insensitivity 
Syndrome (CAIS) 
RDSD042 46,XY Male, Hypospadias – 
RDSD043 46,XY Female, GD – 
RDSD044 46,XY Male, Anorchia Congenital Bilateral Anorchia; 
responsive to testosterone; 
definite penis (mildly shortened); 
no hypospadias, fully formed 
scrotum 
RDSD045 46,XY Male, 
Hypospadias/Cryptorchidism 
Azoospermia, high T levels 
RDSD046 46,XY Female Multiple congenital anomalies; 
no uterus; internal gonads - 
testes 
RDSD047 46,XY Male, Microphallus Hypogonadism, hypospadias 
RDSD048 46,XY Male, Micropenis – 
RDSD049 46,XY Male, Hypospadias – 
CDSD050 46,XY Male, Hypospadias Chordee, bifid scrotum, 
cryptorchidism 
CDSD051 46,XY Female Growth delay, short stature 
 
Abbreviations: CGD – complete gonadal dysgenesis; GD – gonadal dysgenesis. 
Anatomical description follows the standardized nomenclature in Hennekam et al., 2013 
[42], except when only historical description was available in patient's file. 
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Table 3-2: Biological Processes in which differentially expressed mouse gonad genes 
are involved 
 
Gene Ontology 
Biological Process 
Expression in B6-
YPOS vs. B6-YB6 
Males 
# of genes in 
the GO Term 
Reference 
Gene List 
# of 
genes 
Test 
Gene List 
P-value 
Single-multicellular 
organism process 
(GO:0044707) 
Underexpressed 5417 151 4.49E-15 
System development  
(GO:0048731) 
Underexpressed 4042 125 1.45E-14 
Multicellular organism 
development 
(GO:0007275) 
Underexpressed 4640 136 1.61E-14 
Anatomical structure 
development 
(GO:0048856) 
Underexpressed 4986 139 4.32E-13 
Multicellular 
organismal process 
(GO:0032501) 
Underexpressed 6482 163 1.58E-12 
Reproductive system 
development 
(GO:0061458) 
Underexpressed 429 26 1.21E-05 
Male sex differentiation  
(GO:0046661) 
Underexpressed 161 15 1.86E-04 
Reproduction 
(GO:0000003) 
Underexpressed 1373 45 2.52E-03 
Male gonad 
development 
(GO:0008584) 
Underexpressed 139 12 1.05E-02 
Response to 
extracellular stimulus 
(GO:0009991) 
Overexpressed 488 18 3.08E-02 
Epithelial cell 
differentiation 
(GO:0030855) 
Overexpressed 503 18 4.65E-02 
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The list of 515 genes found to be differentially expressed between B6-YPOS and WT 
male embryonic gonads was analyzed using the Gene Ontology Consortium functional 
annotation software. The categories of Gene Ontology (GO) biological processes are 
shown in column 1. P-value – probability of seeing the indicated number of genes from 
custom list (column 4) in GO term gene list (column 3), given the total number of 
annotated genes in the whole genome. 
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Table 3-3: List of VUS in candidate genes 
Gene 
DSD Case 
ID Zygosity HGVSc HGVSp 
MAF 
gnomAD (%) 
TOX2 RDSD021 Het c.319G>A p.Gly107Ser 0 
  CDSD036 Cmpd Het c.448A>G p.Met150Val 0 
  CDSD036 Cmpd Het c.1201C>G p.Pro401Ala 0 
  CDSD036 Cmpd Het c.1122_1124dupGCC p.Pro376dup 0 
DUSP15 RDSD020 Het c.563G>C p.Arg188Pro 0.002 
NKD2 RDSD003 Het c.1151G>A p.Arg384Gln 0.001 
CNGA1 CDSD030 Het c.1478G>A p.Arg493Gln 0.09 
  RDSD022 Het c.398G>T p.Gly133Val 0.03 
PTK2B RDSD011 Het c.1799G>A p.Arg600Gln 0.0008 
ESPN RDSD044 Het c.2230G>A p.Asp744Asn 0.02 
SMOC2 CDSD030 Het c.1276G>A p.Val426Met 0.3 
ADAMTS16 RDSD013 Het c.2200G>A p.Val734Ile 0.8 
  RDSD002 Het c.298C>T p.Arg100Trp 0.1 
  RDSD022 Het c.1405T>G p.Phe469Val 0.02 
FBLN2 CDSD030 Het c.1486G>A p.Ala496Thr 0.033 
  CDSD029 Het c.3605C>G p.Ala1202Gly 0.004 
NIPAL1 RDSD003 Het c.1207A>G p.Thr403Ala 0.1 
  CDSD031 Het c.31G>A p.Glu11Lys 0 
CYP26B1 CDSD032 Het c.805C>G p.Leu269Val 0.008 
SPRY4 CDSD039 Het c.446C>G p.Pro149Arg 0.0004 
MYBL1 RDSD004 Het c.754T>A p.Phe252Ile 0.05 
  CDSD029 Het c.1832G>C p.Ser611Thr 0.0008 
  RDSD049 Het c.936T>A p.Asn312Lys 0.03 
ETV4 RDSD006 Het c.523C>A p.His175Asn 0.1 
LGR5 RDSD007 Het c.1834G>A p.Val612Met 0.004 
  RDSD020 Het c.2341C>G p.Pro781Ala 0.8 
  RDSD048 Het c.2537C>A p.Thr846Asn 0 
 
 
Abbreviations: Het  - heterozygous; Cmpd het – compound heterozygous; HGVSc – 
Human Genome Variation Society coding sequence location; HGVSp – Human 
Genome Variation Society protein sequence location; MAF – minor allele frequency; 
gnomAD – genome Aggregation Database. 
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Figure 3-1: A. Abnormal gonadal development in B6-YPOS fetuses (E15.5) 
The morphology of gonad development in mice shown at embryonic day E11.5 (middle: 
capable of giving rise to both testes and ovaries) and E15.5. Top left: B6-YB6 – testicular 
development in WT male. Top right: B6-XX – ovarian development in WT female. 
Bottom two images show development of ovotestis (left) and ovary (right) in B6-YPOS 
males. 
 
 
 
 
 
 
 
 
 
 
89 
 
B. Immuno fluorescence of wild type and Sox9 knockout gonad at E13.5 
At E13.5 Sox9 protein is lost from the testis cords (white arrows) in the Amh-Cre, 
Sox9floxflox mice yet the testis cords remain intact, as shown by the laminin stain. 
Sox9/Laminin is shown in green and Dapi is shown in blue. Scale bar represents 100um 
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Figure 3-2: 515 Genes are differentially expressed in B6-YB6 vs B6-YPOS gonads 
Pie chart representing the number of differentially expressed genes between WT B6-YB6 
and undervirilized B6-YPOS males. A total of 308 and 207 genes were underexpressed 
(red) and overexpressed (green) in B6-YPOS males, respectively. VUS were identified in 
189 and 116 of the human syntenic genes in underexpressed and overexpressed 
categories respectively.   
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Figure 3-3: Relative expression of novel candidate genes in the B6-YPOS mouse model 
Gene expression differences in candidate genes between B6-YB6 (blue) males,  B6-
YPOS (red) males, and WT B6 females (green). The expression values are shown in 
FPKM values (fragments per kilobase of exon model per million reads).  
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Supplemental Table 3-S1: Genes differentially expressed between B6-YB6 and B6-
YPOS males 
List of all differentially expressed genes either underexpressed or overexpressed in B6-
YPOS males is shown. Additionally, the table contains DSD gene list used for exome 
variant filtration. Genes in common between the two list are also present. 
 
 
Differentially expressed genes Fold Change (WTB6 Male/Ypos Male) Expression in B6-Ypos DSD Gene list used to filter exome variants Genes in common
MIR6516 Not Expressed in Ypos Males Underexpressed ACP5 AMH
SNORA28 Not Expressed in Ypos Males Underexpressed AHR DHH
SNORA44 Not Expressed in Ypos Males Underexpressed AKR1C2 SOX9
SNORA47 Not Expressed in Ypos Males Underexpressed AKR1C4 SOX10
SNORA7A Not Expressed in Ypos Males Underexpressed AKR1D1 FGF9
SNORD15B Not Expressed in Ypos Males Underexpressed ALMS1 PROKR2
CERS1 1266.999808 Underexpressed AMH SLC6A4
AMD1 1156.644062 Underexpressed AMHR2 COL2A1
AMH 41.14940201 Underexpressed AR HSD17B3
NR4A3 25.34241571 Underexpressed ARL13B STAR
MT3 21.34265152 Underexpressed ARL6 MAMLD1
DHH 12.92685038 Underexpressed ARX NR4A1
PTGDS 11.72633858 Underexpressed ATF3 TCF21
SIGLEC12 11.34107437 Underexpressed ATM HSD11B2
TESC 10.18455429 Underexpressed ATRX AUTS2
COL9A3 9.673400875 Underexpressed AUTS2 FOXL2
KIF19 9.120920405 Underexpressed AZF1 TPH2
MMD2 8.62999358 Underexpressed BBS1 CYP11A1
GJB1 7.303379673 Underexpressed BBS10 WNT4
RNASE1 6.981688543 Underexpressed BBS12 RSPO1
GDNF 6.678281727 Underexpressed BBS2 FGFR2
SOX9 6.124617642 Underexpressed BBS4
ISLR2 5.981043326 Underexpressed BBS5
CBLN4 5.972338095 Underexpressed BBS7
SOX10 5.95121736 Underexpressed BBS9
ANKRD63 5.830259494 Underexpressed BKMA1
DKK4 5.287193208 Underexpressed BMP4
FGF9 5.197581132 Underexpressed BMP7
PROKR2 5.015227646 Underexpressed BMPR1A
MALL 4.862568301 Underexpressed BNC2
FZD9 4.846703066 Underexpressed BRCC3
SOX8 4.589458322 Underexpressed CAPN5
NIPAL4 4.390635167 Underexpressed CBX2
PRSS46 4.318670654 Underexpressed CCDC28B
BRICD5 4.196793202 Underexpressed CEP290
AARD 4.137640679 Underexpressed CEP41
DIRAS2 3.944633523 Underexpressed CGNL1
GLDN 3.920223178 Underexpressed CHD7
CST9 3.840364214 Underexpressed CITED2
NKD2 3.798796974 Underexpressed CLCN4
DUSP15 3.786206266 Underexpressed CLTCL1
CITED4 3.722147786 Underexpressed COL2A1
TMEM200B 3.600024105 Underexpressed COQ2
EFHD1 3.475004837 Underexpressed COX14
TOX2 3.444991647 Underexpressed CRH
FSTL4 3.434470546 Underexpressed CSF2RA
SLC26A7 3.416325532 Underexpressed CUL4B
FAM46C 3.404545742 Underexpressed CYB5A
KIAA1804 3.364221265 Underexpressed CYP11A1
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ESPN 3.304105135 Underexpressed CYP11B1
CNGA1 3.289376992 Underexpressed CYP11B2
CFTR 3.252877447 Underexpressed CYP17A1
PTK2B 3.198714887 Underexpressed CYP19A1
ADAMTS16 3.190049216 Underexpressed CYP21A2
SMOC2 3.18133361 Underexpressed CYP7B1
CSPG5 3.151143194 Underexpressed DCAF17
PPARGC1A 3.14794475 Underexpressed DGKK
CBLN1 3.143573222 Underexpressed DHCR24
AHSG 3.047744547 Underexpressed DHCR7
DTNA 3.025463286 Underexpressed DHH
JAML 3.012464658 Underexpressed DISC1
MRO 2.980612041 Underexpressed DMRT1
LPCAT2 2.919351 Underexpressed DMRT2
LRP4 2.906787146 Underexpressed DND1
COL27A1 2.906445023 Underexpressed DNMT3L
POPDC3 2.90460229 Underexpressed EFNB1
SPP1 2.877270188 Underexpressed EHD1
FBLN2 2.839900254 Underexpressed ELAVL4
SLC6A4 2.837312993 Underexpressed EPHX1
MFSD2A 2.817328515 Underexpressed ERCC3
ST3GAL4 2.8149864 Underexpressed ERCC5
GATM 2.812379197 Underexpressed ESR1
SMTNL2 2.798053878 Underexpressed ESR2
CEMIP 2.782810155 Underexpressed ESRRA
ADHFE1 2.770123692 Underexpressed F9
ACAP1 2.753425427 Underexpressed FANCA
NIPAL1 2.711846818 Underexpressed FANCG
MYBPHL 2.703880995 Underexpressed FANCM
COCH 2.687715023 Underexpressed FEM1C
PLA2G2F 2.657842557 Underexpressed FGF10
SERPINE2 2.655779698 Underexpressed FGF8
COL2A1 2.622345814 Underexpressed FGF9
TRIM47 2.61588044 Underexpressed FGFR1
PAK3 2.609585234 Underexpressed FGFR2
DCT 2.572618263 Underexpressed FGFR3
KCNK2 2.559737823 Underexpressed FKBP4
ATG9B 2.535018285 Underexpressed FLNA
EIF3J 2.513811934 Underexpressed FOXF2
CYP26B1 2.508865967 Underexpressed FOXL2
GAS7 2.469701009 Underexpressed FREM2
BARX2 2.469675205 Underexpressed FSHB
PPP1R3C 2.446262391 Underexpressed FSHR
RELT 2.440486625 Underexpressed G6PC2
GAL3ST1 2.438966909 Underexpressed GAL
RTN4RL1 2.392479459 Underexpressed GATA4
SPRY4 2.390869506 Underexpressed GATA5
RERG 2.384200023 Underexpressed GHRHR
REN 2.381279951 Underexpressed GLYCTK
COL9A2 2.380238517 Underexpressed GNAS
HSD17B3 2.361614016 Underexpressed GNRH1
SPATA2L 2.351927188 Underexpressed GNRHR
MAPK13 2.348581405 Underexpressed GPC3
PPP1R16B 2.31830908 Underexpressed HAMP
ADAMTSL2 2.314326038 Underexpressed HBA1
TMEM184A 2.297886065 Underexpressed HBA2
MYBL1 2.288200893 Underexpressed HBB
NGEF 2.271001818 Underexpressed HES1
DEFB119 2.251651252 Underexpressed HESX1
SCRN1 2.199678762 Underexpressed HEXB
RAB20 2.197794982 Underexpressed HFE
ZAR1 2.191764202 Underexpressed HFE2
GSTM1 2.180067453 Underexpressed HOXA13
HCN4 2.17783067 Underexpressed HOXA4
WIPF3 2.153849115 Underexpressed HOXB6
COL9A1 2.145411571 Underexpressed HOXD10
ETV4 2.141425931 Underexpressed HS6ST1
GFRA1 2.137688849 Underexpressed HSD11B2
RHPN1 2.133648616 Underexpressed HSD17B3
EMILIN3 2.133309197 Underexpressed HSD3B2
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TNFRSF12A 2.12736642 Underexpressed HTR2A
GPR157 2.120702551 Underexpressed HTR3A
MYL4 2.114417637 Underexpressed IGF1R
BHLHE40 2.089660533 Underexpressed IGFALS
FOXS1 2.071701277 Underexpressed INHBA
TPD52L1 2.070663088 Underexpressed INHBB
KCTD12 2.063090789 Underexpressed INSL3
BVES 2.061582638 Underexpressed INSR
SNORA78 2.055478272 Underexpressed INSRR
GSTM2 2.054969791 Underexpressed IRF6
EGR1 2.03247483 Underexpressed ITGB3
PITPNM3 2.013541789 Underexpressed KAL1
LGR5 2.009966014 Underexpressed KCNJ5
TMEM59L 2.008618477 Underexpressed KDM5D
MAFF 1.989893456 Underexpressed KIF7
HIST1H2AJ 1.987322783 Underexpressed KISS1
LIPG 1.965736363 Underexpressed KISS1R
ABTB2 1.964094251 Underexpressed KRT86
LEFTY2 1.955667499 Underexpressed LATS1
CTGF 1.953865199 Underexpressed LEP
ABCB1 1.953209539 Underexpressed LEPR
PITX2 1.951544627 Underexpressed LHB
GALR3 1.927555487 Underexpressed LHCGR
CITED1 1.927251738 Underexpressed LHFPL5
GSTM2 1.923317345 Underexpressed LHX3
RGN 1.921622348 Underexpressed LHX4
PLA2G5 1.91384394 Underexpressed LHX9
TNFAIP6 1.905623944 Underexpressed LIG4
C16orf89 1.902021758 Underexpressed LIPE
AP1M2 1.90097902 Underexpressed LMNA
RTN1 1.893716951 Underexpressed LZTFL1
FAM46B 1.884866914 Underexpressed MAGEB1
RSG1 1.884228409 Underexpressed MAGEB2
STAR 1.883137846 Underexpressed MAGEL2
AGPAT4 1.881669037 Underexpressed MAMLD1
CHST1 1.874657235 Underexpressed MAOA
APBA1 1.874487801 Underexpressed MAP3K1
ETV5 1.86789436 Underexpressed MAP3K4
EYA1 1.862463216 Underexpressed MBTPS2
VDR 1.861342891 Underexpressed MC4R
RNF223 1.856798156 Underexpressed MEF2B
NTF3 1.842122036 Underexpressed MEN1
LHX1 1.840754706 Underexpressed MID1
COL18A1 1.839971455 Underexpressed MKKS
SHBG 1.837639646 Underexpressed MKS1
MYLK3 1.836429476 Underexpressed MNX1
WSCD1 1.824120006 Underexpressed MSC
ALDH1A1 1.818860004 Underexpressed MTCP1
CA12 1.809182273 Underexpressed MTHFR
FAM189A2 1.80784961 Underexpressed MTMR1
RASL12 1.803755689 Underexpressed MYO1E
RCAN1 1.799798957 Underexpressed NCOA2
SOD3 1.792261668 Underexpressed NCOA4
CLDN4 1.791679726 Underexpressed NDN
MICAL2 1.790454985 Underexpressed NDUFS4
SLCO3A1 1.790215506 Underexpressed NEDD4
GRAMD2 1.787934596 Underexpressed NELF
APH1B 1.787322077 Underexpressed NKAIN2
SEMA5A 1.786794482 Underexpressed NMT2
ACVR1C 1.777613166 Underexpressed NOS1
NUP62CL 1.774050708 Underexpressed NPC1
AKR1B10 1.773597347 Underexpressed NPHS2
DYNLT1 1.773091673 Underexpressed NR0B1
LRRC25 1.772346133 Underexpressed NR2C1
LMO4 1.768978609 Underexpressed NR2E3
PDZD2 1.765992318 Underexpressed NR3C1
DNM3OS 1.764734544 Underexpressed NR4A1
CARMN 1.764534059 Underexpressed NR5A1
HAS3 1.759283451 Underexpressed OTX2
S100A8 1.753832225 Underexpressed PCSK1
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BCAR3 1.753076567 Underexpressed PDE11A
SPACA6 1.743499404 Underexpressed PDE8B
SLC16A7 1.742868522 Underexpressed PEX2
MAMLD1 1.73911045 Underexpressed PGR
CGA 1.738851327 Underexpressed PHF6
DKK1 1.734203792 Underexpressed PKD1
C8orf88 1.733425702 Underexpressed PLCB3
ENPP1 1.732472245 Underexpressed PLLP
LAMA4 1.731224309 Underexpressed POLG
CAMK2N1 1.730778472 Underexpressed POLR3A
CEND1 1.729012687 Underexpressed POLR3B
MFSD13A 1.725020768 Underexpressed POR
FJX1 1.724142221 Underexpressed POU1F1
SH2B2 1.723018218 Underexpressed PROK2
FGF1 1.720638406 Underexpressed PROKR2
HIST1H1E 1.71772735 Underexpressed PROP1
ATP1A2 1.71499176 Underexpressed PSMC3IP
DUSP14 1.711981287 Underexpressed RAB3GAP2
SCX 1.711367324 Underexpressed RCN2
TRANK1 1.698087228 Underexpressed RET
AQP1 1.696429719 Underexpressed RFXAP
REL 1.692285078 Underexpressed RPGRIP1L
DUSP6 1.689337851 Underexpressed RPL35A
TLX2 1.68136116 Underexpressed RPS4X
PDE2A 1.680291408 Underexpressed RPS4Y1
TINAGL1 1.679650642 Underexpressed RSPO1
TMEM114 1.668182154 Underexpressed SALL1
CMKLR1 1.665284304 Underexpressed SAT1
SYNJ2 1.66348239 Underexpressed SDCCAG8
EPS8 1.663175277 Underexpressed SDHB
RPRM 1.660709082 Underexpressed SHOX
HSD3B1 1.659951155 Underexpressed SIL1
IRS2 1.658844335 Underexpressed SLC29A3
JUNB 1.657983445 Underexpressed SLC6A4
TYRO3 1.655633933 Underexpressed SLC9A3R2
CTRB1 1.654668669 Underexpressed SMPD2
NR4A1 1.653278706 Underexpressed SMPD3
EPHB6 1.651455778 Underexpressed SNORD116-1
PTPRE 1.645823108 Underexpressed SNORD116@
CLDN8 1.643600868 Underexpressed SOD2
SOCS2 1.641928301 Underexpressed SOX10
EPHA4 1.639652309 Underexpressed SOX2
FBXL22 1.638852818 Underexpressed SOX3
FAM84A 1.636644604 Underexpressed SOX9
SPRY2 1.633819365 Underexpressed SPO11
PLEKHA4 1.631924426 Underexpressed SRD5A1
AFAP1L2 1.631016164 Underexpressed SRD5A2
TUBB3 1.63028545 Underexpressed SRD5A3
CDO1 1.626459314 Underexpressed SRY
SEMA3D 1.626093996 Underexpressed STAR
CCL25 1.625684728 Underexpressed STAT5B
SLC45A4 1.624164382 Underexpressed STS
CHCHD10 1.621336026 Underexpressed TAB2
PRSS53 1.619839241 Underexpressed TAC3
PMEPA1 1.614384903 Underexpressed TACR3
ERBB3 1.611556682 Underexpressed TCF21
C4orf47 1.610416521 Underexpressed TDRD7
RASGEF1B 1.609758174 Underexpressed TFR2
VAMP5 1.609647744 Underexpressed THRB
ART3 1.607507562 Underexpressed TMEM67
HS3ST1 1.606398673 Underexpressed TMEM70
GPR20 1.605300627 Underexpressed TNXB
NGFR 1.604264065 Underexpressed TP63
GALNT14 1.603235988 Underexpressed TPH2
IL17RD 1.600321585 Underexpressed TPI1
WIF1 1.599531822 Underexpressed TRA2A
DUSP4 1.59694461 Underexpressed TRIM32
ITGB8 1.596143315 Underexpressed TRIM37
TMEM150C 1.593567296 Underexpressed TRNL1
ANKH 1.588046739 Underexpressed TRPC6
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WNT11 1.58549257 Underexpressed TSPYL1
CYP27A1 1.584928824 Underexpressed TTC21B
LDLRAD4 1.582911629 Underexpressed TTC8
HAS2 1.579712039 Underexpressed TTR
OPTC 1.577373246 Underexpressed TUB
SOX6 1.575725432 Underexpressed UGT2B17
JUN 1.574952164 Underexpressed UGT2B28
MAL2 1.570776774 Underexpressed VANGL2
TBX20 1.57031401 Underexpressed WDPCP
INF2 1.568763762 Underexpressed WDR11
MASP1 1.567569942 Underexpressed WNT4
NEDD9 1.565066197 Underexpressed WT1
TSPAN15 1.56362657 Underexpressed WWOX
TGOLN2 1.562371179 Underexpressed XG
CALY 1.56181677 Underexpressed ZDHHC21
WNT9B 1.561582466 Underexpressed ZDHHC7
NODAL 1.557602118 Underexpressed ZEB2
ADCYAP1R1 1.557479233 Underexpressed ZFPM2
ZFHX2 1.557323508 Underexpressed ZFX
GSG1L 1.557184237 Underexpressed ZFY
PLCB2 1.553184034 Underexpressed
FAM19A5 1.550824214 Underexpressed
LRRC75B 1.545668424 Underexpressed
SEMA4A 1.544618596 Underexpressed
CSPG4 1.540188486 Underexpressed
TCF21 1.539581849 Underexpressed
SLC16A4 1.533941193 Underexpressed
PAQR8 1.533883211 Underexpressed
AQP5 1.532708087 Underexpressed
SPSB1 1.532008193 Underexpressed
RND2 1.531732478 Underexpressed
VSTM4 1.5255081 Underexpressed
PPP1R36 1.524634844 Underexpressed
MMP2 1.521252375 Underexpressed
FHDC1 1.520483207 Underexpressed
PITPNM2 1.516215956 Underexpressed
CNTNAP1 1.515016598 Underexpressed
C7orf31 1.514247829 Underexpressed
PARM1 1.513625802 Underexpressed
PGP 1.513071922 Underexpressed
HSD11B2 1.511952732 Underexpressed
PTPN7 1.508987116 Underexpressed
PAG1 1.507527242 Underexpressed
AUTS2 1.506979311 Underexpressed
CHRNB4 1.504837673 Underexpressed
EFHD2 1.50472639 Underexpressed
CTTNBP2 1.500523263 Underexpressed
CPM 1.500148848 Underexpressed
SLMAP 1.500086017 Underexpressed
SNORA17 Not Expressed in WT B6 Males Overexpressed
SNORA52 Not Expressed in WT B6 Males Overexpressed
RPS27 11.32170688 Overexpressed
FST 5.015775937 Overexpressed
SNORA81 4.354569893 Overexpressed
FOXL2 4.221084368 Overexpressed
WFDC1 3.703793901 Overexpressed
KCNG4 3.448244778 Overexpressed
RNF152 3.446044859 Overexpressed
SLC7A11 3.297906051 Overexpressed
ONECUT1 3.218813544 Overexpressed
STUM 3.056932247 Overexpressed
MIXL1 3.045712849 Overexpressed
FAM196B 3.016041036 Overexpressed
EIF3J 3.002723589 Overexpressed
NMUR2 2.92225111 Overexpressed
TSHR 2.807169723 Overexpressed
VGLL2 2.776733916 Overexpressed
C17orf97 2.681585036 Overexpressed
CDH9 2.671882459 Overexpressed
HSD17B13 2.638580788 Overexpressed
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SIGLEC10 2.599807364 Overexpressed
HIST1H2BB 2.596494891 Overexpressed
SPRR2D 2.575460231 Overexpressed
PDZD7 2.522809788 Overexpressed
SSTR3 2.495861846 Overexpressed
SLITRK1 2.412227995 Overexpressed
AGTR1 2.40639021 Overexpressed
KLHDC7A 2.334831452 Overexpressed
GPR55 2.331359995 Overexpressed
KCNJ12 2.330557327 Overexpressed
GBP3 2.277363542 Overexpressed
CSGALNACT1 2.275820796 Overexpressed
DCAF12L1 2.265471897 Overexpressed
HIST1H4F 2.222366198 Overexpressed
QPRT 2.211066075 Overexpressed
ELFN2 2.203547914 Overexpressed
BMP2 2.19205753 Overexpressed
IRF7 2.173973271 Overexpressed
TPH2 2.165042799 Overexpressed
GBP2 2.163510119 Overexpressed
LBX2 2.153010266 Overexpressed
CTXN3 2.148315454 Overexpressed
TNS4 2.136426679 Overexpressed
SCRT2 2.133960795 Overexpressed
CHRM4 2.12644749 Overexpressed
WNT9A 2.090359813 Overexpressed
C9orf152 2.089763669 Overexpressed
EDN2 2.061351233 Overexpressed
AKR1C3 2.034186876 Overexpressed
PTCHD1 2.014200415 Overexpressed
CGN 2.011798532 Overexpressed
STX11 1.997671242 Overexpressed
IRX3 1.970579587 Overexpressed
NRN1 1.966620624 Overexpressed
TAF7L 1.953627526 Overexpressed
CDKN1B 1.948892084 Overexpressed
PPARA 1.94436905 Overexpressed
CPT1B 1.943004401 Overexpressed
MGARP 1.92895282 Overexpressed
PDK4 1.927050628 Overexpressed
SYT13 1.923379289 Overexpressed
ADTRP 1.921132122 Overexpressed
KCNIP1 1.913031151 Overexpressed
PLBD1 1.895975731 Overexpressed
KRT20 1.893712982 Overexpressed
ACAT2 1.889804397 Overexpressed
EREG 1.88709216 Overexpressed
KLHL5 1.877198817 Overexpressed
ADM 1.874204743 Overexpressed
BHLHA15 1.870258393 Overexpressed
PLIN1 1.857005825 Overexpressed
SP5 1.855243798 Overexpressed
CYP11A1 1.852878122 Overexpressed
IL15 1.836812458 Overexpressed
KYAT3 1.828685522 Overexpressed
CCDC182 1.82230537 Overexpressed
PANK1 1.809516395 Overexpressed
ISG15 1.804757885 Overexpressed
CDKN1A 1.803095995 Overexpressed
TXNDC2 1.798272949 Overexpressed
FAM178B 1.794897531 Overexpressed
FOXR1 1.780932866 Overexpressed
LYPD6B 1.779994878 Overexpressed
PRRT4 1.779099395 Overexpressed
NPY1R 1.77835442 Overexpressed
COL12A1 1.771471122 Overexpressed
SPINK4 1.771210239 Overexpressed
CFAP161 1.770392383 Overexpressed
CCL2 1.770064146 Overexpressed
HIST1H1A 1.769393464 Overexpressed
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TMEM171 1.765579488 Overexpressed
PPP2R2B 1.765193267 Overexpressed
GPRC5A 1.762134052 Overexpressed
GNG13 1.761490003 Overexpressed
RBKS 1.759679541 Overexpressed
SH3BGR 1.759456337 Overexpressed
VAV3 1.758471534 Overexpressed
AIF1 1.756964897 Overexpressed
EFCAB10 1.75594238 Overexpressed
MCTP1 1.748212112 Overexpressed
ISX 1.744613287 Overexpressed
WNT4 1.742707143 Overexpressed
PIPOX 1.741384502 Overexpressed
WFDC13 1.734425578 Overexpressed
C16orf45 1.733405527 Overexpressed
ADAM8 1.730807823 Overexpressed
SPRR2E 1.72918969 Overexpressed
RORC 1.722362727 Overexpressed
TRNP1 1.71335502 Overexpressed
SLC37A2 1.710394409 Overexpressed
SMIM10L2A 1.71011236 Overexpressed
HIST1H3I 1.708885931 Overexpressed
RNASET2 1.708081348 Overexpressed
EPX 1.702774666 Overexpressed
PGLYRP1 1.699234872 Overexpressed
TMEM40 1.697091467 Overexpressed
PET117 1.696923289 Overexpressed
OAS2 1.695282499 Overexpressed
ACTR6 1.683190047 Overexpressed
CYBRD1 1.681156707 Overexpressed
TMEM174 1.680620355 Overexpressed
AHNAK 1.677631618 Overexpressed
PLD1 1.676163644 Overexpressed
GABRA4 1.675159704 Overexpressed
SLC1A6 1.673739143 Overexpressed
TGM3 1.671730237 Overexpressed
PLAC1 1.665417966 Overexpressed
SIGLEC5 1.663814485 Overexpressed
MSX1 1.661100614 Overexpressed
IDI1 1.660112402 Overexpressed
NPB 1.659384896 Overexpressed
MSX2 1.657707699 Overexpressed
ELFN1 1.656938083 Overexpressed
ORC1 1.656137519 Overexpressed
LZTS1 1.654276926 Overexpressed
TSPAN33 1.652136543 Overexpressed
ASNS 1.651053646 Overexpressed
PHLDA2 1.647210926 Overexpressed
SPRR1A 1.643740569 Overexpressed
GXYLT2 1.640503814 Overexpressed
PNLIPRP1 1.633228932 Overexpressed
DHDH 1.62881779 Overexpressed
SMPX 1.627926953 Overexpressed
FAM83G 1.624749915 Overexpressed
DCAF12L2 1.624211209 Overexpressed
FRMD6 1.623913577 Overexpressed
EGFL6 1.617778676 Overexpressed
SLC7A2 1.615677244 Overexpressed
TRIM50 1.611484558 Overexpressed
C11orf65 1.604872802 Overexpressed
RSPO1 1.602248498 Overexpressed
HPSE 1.599898053 Overexpressed
ANGEL1 1.59674608 Overexpressed
COQ8A 1.596129176 Overexpressed
GK5 1.590209768 Overexpressed
SH2D4A 1.58545061 Overexpressed
SFXN3 1.584349425 Overexpressed
FOXJ1 1.584320251 Overexpressed
CPNE8 1.577968063 Overexpressed
CDKN1C 1.576690526 Overexpressed
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TCEA3 1.576256699 Overexpressed
TGFA 1.574456597 Overexpressed
RPL39L 1.574046014 Overexpressed
GTF2A1 1.570612911 Overexpressed
HPGD 1.569853795 Overexpressed
RASGRP1 1.564330869 Overexpressed
DBNDD1 1.562684113 Overexpressed
GRIN2C 1.561425831 Overexpressed
FGFR2 1.558340878 Overexpressed
KCNIP2 1.55752982 Overexpressed
NECAB3 1.555544383 Overexpressed
GABRB1 1.554939015 Overexpressed
RNF128 1.553661667 Overexpressed
PLCH1 1.551738416 Overexpressed
PCBD1 1.549787805 Overexpressed
ZNF703 1.548053594 Overexpressed
MTERF1 1.547233678 Overexpressed
IFI27 1.545121063 Overexpressed
CRYL1 1.544270434 Overexpressed
TMEM220 1.543977958 Overexpressed
TRIM14 1.541887737 Overexpressed
TSPYL5 1.541854931 Overexpressed
TMEM141 1.53932226 Overexpressed
CHST4 1.538911709 Overexpressed
ZNF277 1.534721179 Overexpressed
HIST1H2BJ 1.531751971 Overexpressed
IGF1 1.531496286 Overexpressed
SPOCK2 1.529845464 Overexpressed
MORN1 1.528812451 Overexpressed
TTC38 1.528809022 Overexpressed
SLC30A5 1.523289108 Overexpressed
HSD17B11 1.523104472 Overexpressed
MOAP1 1.521789255 Overexpressed
SALL3 1.520033582 Overexpressed
MID1IP1 1.516664671 Overexpressed
IFITM3 1.514798276 Overexpressed
KCND2 1.512721511 Overexpressed
IBSP 1.511966492 Overexpressed
SOHLH2 1.508940653 Overexpressed
NLRP4 1.50774366 Overexpressed
SERPINB6 1.507622765 Overexpressed
CBS 1.507059254 Overexpressed
SPRR2G 1.50579062 Overexpressed
NEU3 1.505199617 Overexpressed
REC8 1.50127842 Overexpressed
NIM1K 1.500014461 Overexpressed
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Supplemental Table 3-S2: Primer sets used for qPCR validation 
Gene Forward primer Reverse primer Annealing 
temperatu
re 
(in 
Celsius) 
Tox2 GGCCTACGCTCTCTTCTTC CCTCTTATACGCCTGTTTC
TG 
60 
Dusp15 AACTTCATTGATGCCAAAG
AC 
GGTGATTCGTGGATAGAG
ATG 
61 
Nkd2 GTGGCAGAACAGAGATTGA
G 
TTGGGCTTCCTGCTGTAG 60 
Cnga1 TCAACAACAGCAGCAACAA
AG 
TATCATCGGCCTTGCTCTT
C 
64 
Ptk2b TGGATGTGGAGAAGGAAG
AC 
TGATGATCTCCTGGATCTC
TG 
61 
Espn ATTACCCTGAGGGAGTGAA
TG 
AAGGTACTTCGTCACTTCC
AG 
60 
Smoc2 CAAATGGAAGACCCATCAG CAGCATCATCTGCTTTCC 60 
Adamts1
6 
AACATGGTGTCTGCCTTAT
TC 
CCCTGGCTGTTCATCTTC 63 
Fbln2 GTGATCTTGATGGCTCCAC CTGGGCTATCCTACAGAT
GTC 
60 
Nipal1 GGGTCAACTGTGATGGTTA
TC 
AACGAACCCTGGATCTCT
C 
61 
Cyp26b1 GTACCCAGGGCAAAGACTA
C 
GGTTCCATCCTTCAGCTC 60 
Spry4 TGCAGCTCCTCAAAGACC ATGACTGAGCTGGGATTC
AC 
60 
Mybl1 GTCAGCCGAGAATGAAGTT
AG 
AGCTTCCAGGTTGAGGTG 61 
Etv4 CAGGACCTCAGTCACTTCC CGGTACCTGAGCTTCTGC 62 
Lgr5 AACCTCCGATCTCTGAACT
TAG 
CGACAGGAGATTGGATGA
TAG 
63 
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Supplemental Figure 3-S1: Fold expression changes in known DSD genes 
underexpressed in B6-YPOS males 
Expression values are shown as fold change differences between B6-YB6 and B6-YPOS 
males for genes present in primary gene list used for exome variant filtration. 
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Supplemental Figure 3-S2: Validation of candidate gene expression differences 
between B6-YB6 and B6-YPOS males via qPCR 
Expression values are shown as fold change differences between B6-YB6 and B6-YPOS 
males using RNA-Seq data (blue) and qPCR data (red). 
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Supplemental Figure 3-S3: Sry and Sox9 expression in the E11.5 embryonic gonad 
Expression values shown in FPKM (fragments per kilobase of exon model per million 
reads) measured by RNA sequencing. 
 
 
 
 
 
 
 
 
 
Supplemental Figure 3-S4: Profiles of candidate gene expression in the gonad across 
sex determination  
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Candidate gene profile graphs were generated from the microarray performed by 
Jameson et al. 2012 [27] where gene expression was profiled in each cell population of 
the gonad at E11.5, E12.5 and E13.5. Similar to the Sox9 target genes, Amh and Ptgds 
the candidate genes show strong expression in the male supporting lineage (blue dotted 
line) compared to the female (blue solid line). There was no information available in the 
microarray data for Tox2. 
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Supplemental Figure 3-S5: Fbln2 protein expression in WT B6 females and males at 
E12.5 by immunohistochemistry 
Embryonic section of WT B6 females and males at E12.5 stained for Fbln2 (red) and 
cell nuclei (purple). Fbln2 is expressed in a sexually dimorphic pattern as no expression 
is present in WT B6 female (left), whereas the expression in WT B6 male is high. The 
gonads are encircled by yellow dashed lines.
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Chapter 4 
 
Identification of Large Causative Genetic Variants via 
Next-Generation Genome Mapping and Sequencing 
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Abstract 
 
DNA sequencing has become a routine procedure in clinics across the United 
States and around the globe where physicians order either exome or single gene 
sequencing to identify pathogenic variants leading to patient’s phenotype and provide 
the appropriate care. Massively parallel DNA sequencing has the capability of reliably 
identifying single nucleotide variants (SNVs) and small insertions and deletions 
(INDELs); however, due to its innate methodology that relies on generation of short 
reads, this platform fails to identifiy large structural variants (SVs) such as insertions, 
deletions, inversions and translocations. In order to overcome these limitations and 
provide genetic diagnosis for patients with previous negative exome sequencing, we 
used Irys genome mapping technology that relies on imaging of fluorescently labeled 
native-state DNA molecules (up to 1Mb in size) in nanochannel arrays for genome 
assembly and SV detection. First, to ascertain the SV detection capability of the Irys 
system, we investigated a series of patients diagnosed with Duchenne Muscular 
Dystrophy (DMD) who were known to carry a large deletion, insertion or inversion in the 
Dystrophin gene by PCR, but with imprecise DNA break points. Second, we performed 
genome sequencing and genome mapping on patients diagnosed with disorders of sex 
development (DSD) to discover pathogenic SVs, SNVs or INDELs. Using this strategy 
we have successfully identified the intronic breakpoints within the Dystrophin gene 
where our cohort of DMD patients carried either a deletion, a duplication or an inversion. 
The sizes of identified deletions and insertions ranged from 30kb – 200kb and 10kb – 
150kb respectively encompassing several exons and introns. We also were able to 
identify heterozygous SVs in carrier mothers of DMD patients indicating the ability of the 
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method to distinguish between homozygous and heterozygous SVs, and therefore 
distinguish between carrier and affected status of an individual. On average, in our 
cohort of both DMD and DSD cases, the Irys system identified around 1300 insertions, 
700 deletions, 50 inversions and 20 translocations of variable sizes per genome. To 
filter out possibly benign variants, we used a database containing SVs from 144 healthy 
individuals and were able to narrow the list of SVs down to several that could potentially 
play a role in patient’s phenotype. Although we see that SVs are less common than 
SNVs and INDELs, they account for a significant fraction of genetic variation. Next-
Generation Mapping (NGM) is poised to identify potential pathogenic SVs in affected 
individuals and soon be incorporated in the clinical diagnostic strategy. 
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Introduction 
 
Although Sanger sequencing is still widely used for reads around 1kb in length, 
new developments of massively parallel sequencing reactions have taken over the 
global market share of sequencing due to cheap price and fast turnaround times. This is 
in part due to the large improvements made in both imaging technology and 
microengineering. Next-generation sequencing technology has allowed for the 
discovery of many pathogenic single-nucleotide mutations. Next-generation sequencing 
from Illumina utilizes flowcells covered with millions of surface-bound oligonucleotides 
that allow parallel sequencing of millions of short reads. Resulting reads are then 
aligned to a reference genome for the genome assembly. This method misses on 
deletions, insertions, or duplications larger than the produced reads. The most common 
method for detecting large insertions or deletions is through the use of chromosomal 
microarrays. For diseases in which the suspected mutations are copy number 
variations, array-based DNA hybridization techniques can be used. However, CMAs 
cannot detect balanced translocations or inversions.  
Similarly to exome sequencing, genome sequencing uses next-generation 
sequencing, but is capable of identifying single nucleotide variants, insertion/deletions 
and copy number variants not only in exons but also in non-coding regions of the 
genome. This allows for identification of variants affecting gene regulation, but currently 
has limited use in the clinical realm due to our inability to interpret most variants. A 
method that is useful in conjunction with genome sequencing is genome mapping, 
which utilizes labelled high molecular weight DNA to preserve large elements of 
structure of the genome. This allows the examination of the larger genome and 
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detection of structural variants. Genome mapping also can be used to create scaffolds 
for sequence assembly. Genome mapping enables a more complete picture of the 
genome, and allows us to view breakpoints, large insertions, and deletions in the 
genome, which would not be possible with only genome sequence.   
To facilitate the identification of genetic diagnosis in DSD patients with negative 
exome, we will utilize genome sequencing and new genome mapping technology 
capable of identifying large insertions, deletions, copy number variants, inversions and 
balanced translocations. Combined these two technologies will provide base level 
resolution and physical map of the human genome allowing for identification of the 
majority of known genetic variation.  
Here, to validate the new, still under development method, we first used 
nanochannel-based Next Generation Mapping (NGM) technology to detect large 
insertions, deletions, copy number variations, as well as inversions and translocations in 
Duchenne muscular dystrophy (DMD). DMD  is an X-linked recessive form of muscular 
dystrophy which affects 1 in 3500 male newborns. It is a disease that is characterized 
by symptoms of delayed motor reactions and limb weakness, with many affected 
patients becoming wheelchair-bound by 11-12 years old. The disease is caused by 
mutations on the dystrophin gene, which is on position Xp21. The dystrophin gene 
encodes one of the largest proteins in the human genome, with 79 exons, which encode 
for a 14kb mRNA strand. A study of a database with over 7000 recorded mutations on 
the dystrophin gene showed that 86% of total mutations were large deletions of 1 exon 
or greater.  
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We have also performed genome sequencing on 95 trios diagnosed with DSD 
and perform physical map assembly for an additional 17 families. 
 
Methods 
Genome mapping: 
 To assemble a genomic physical map for identification of large deletions, 
insertions, translocation and inversions, we used Bionano Genomics Irys technology 
that relies on labeling of restriction enzyme sites throughout long strands of DNA 
molecules and then reverse-assemble these molecules with the reference genome in 
order to identify structural variants. 
DNA isolation for genome mapping: 
Irys technology requires long strands of DNA molecules (>150kb in size) 
encompassing multiple restriction enzyme sites for proper genome assembly. To 
achieve this requirement, DNA is extracted from fresh peripheral blood following 
manufacturers PlugLysis protocol (Bionano Genomics, USA). Briefly, red blood cells 
(RBC) are lysed using RBC lysis solution (Qiagen) and white blood cells (WBC) are 
centrifuged and re-suspended in cell suspension buffer (Bio-Rad). The WBC are 
embedded into agarose plugs (CHEF Genomic DNA Plug Kit, Bio-Rad) for overnight 
lysis at 50°C using 16:1 ratio of lysis buffer (Bionano Genomics, USA) and Proteinase K 
(Qiagen). The plugs are washed with TE Buffer and digested at 43°C with GELase 
(Epicentre). Extracted high molecular weight DNA is purified from digested 
materials/enzymes via drop dialysis using Millipore membrane filters (EMD Millipore, 
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USA) placed on a Tris-EDTA buffer. DNA quantifications were carried out using Qubit 
dsDNA assay kits with Qubit 3.0 Fluorometer (Thermo Fisher).    
DNA labeling and chip loading for genome mapping: 
 DNA labeling consists of 4 sequential steps (Figure 4-1) and was performed 
using the IrysPrep Reagent Kit (BioNano Genomics). Briefly, 900ng of purified high 
molecular weight DNA was nicked with nicking endonucleases Nt.BspQI and Nt.BssSI 
(New England BioLabs) in 10X Buffer 3 at 37°C for 2 hours. The nicked DNA was then 
labeled with 10X Labeling Mix containing fluorophore-labeled nucleotide using Taq 
polymerase (NEB) at 72°C for 1 hr before being repaired with Taq ligase (NEB) and 
IrysPrep Repair Mix, NAD+, and 10X Thermopol buffer at 37°C for 30 minutes.  The 
backbone of DNA was then stained with IrysPrep DNA stain, 5X DTT, and 4X flow 
buffer overnight at 4°C. Labeled DNA was loaded on Irys chip and ran for 24 hours 
(Figure 4-2). In the chip, the sample is run through a low-voltage electric field. DNA is 
first concentrated in a gradient region (lip) before being pushed through a pillar region, 
need for DNA linearization to enter nanochannel arrays. The fluorescently labeled DNA 
molecules are imaged sequentially across nanochannels by Irys instrument producing 
thousands of high-resolution images of single DNA molecules that are then used for 
genome assembly and variant calling. To achieve the necessary coverage of 100x 
necessary for accurate identification of structural variants 4-6 Irys chips were run, each 
at 30 cycles. 
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Data analysis for genome mapping: 
Genome assembly was performed using IrysView/IrysSolve software solutions 
provided by Bionano Genomics. The raw TIFF images of labeled long DNA molecules 
were converted to BNX files containing DNA backbone, nicked site, and quality score 
information for each molecule/label. The conversion was accomplished via AutoDetect 
software (Bionano Genomics). Due to large size of the raw data that is acquired in the 
form of TIFF images, it was not economical to store and we opted to store only BNX 
files. This decision has no consequences on the quality of the data, downstream 
processing or analysis. Assembly of the genome using BNX files and further structural 
variation detection was performed using pipelines generated by Bionano Genomics [1]. 
Briefly, the human genome reference hg19 was digested in silico using either Nt.BspQI 
and Nt.BssSI enzymes to generate a reference consensus map. The reference 
consensus map was used for initial molecule alignment and generation of contigs. 
Later, the molecule information was used to fine-tune the initially generated contings to 
accurately represent the molecule data. Comparison of the two maps (sample vs 
reference) was used to identify structural variants. Identified structural variants were 
filtered against a healthy control dataset containing 144 individuals (Bionano 
Genomics). Data visualization was accomplished via IrysView 2.5.1 software (Bionano 
Genomics). 
Validation of SVs via PCR and quantitative PCR  
Validation of identified SVs was performed using PCR and qPCR. The primer 
sequences used are detailed in (Table 4-1). Primers were designed using primer design 
software Primer3 [2]. DNA was quantified using QuBit HS (Invitrogen) for double 
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stranded DNA and a total of 2ng of DNA was used per sample for qPCR reaction. qPCR 
was carried out in quadruplicates and duplicates utilizing Syber Green-based 
SensiFAST™ SYBR No-ROX Kit (Bioline, UK) by DNA Engine Opticon® 2 real-time 
PCR detection system from Bio-Rad Laboratories (BioRad, USA). Reaction conditions 
were as follows: 95ºC for 10 min, then 40 cycles of 95ºC for 15 sec, 60ºC for 10 sec 
(see Table S2), and 72ºC for 15 sec. A total of 100ng of DNA per sample was used for 
regular PCR. PCR was carried out utilizing MyTaq™HS Red Mix by BioRad Thermal 
Cycling Platform,1000 Series (BioRad USA). Reaction conditions were as follows: 95° 
for 1min, and then 35 cycles for 95°C for 15 sec, 95°C for 15 sec, 60°C for 15 sec, and 
72°C for 10sec. 
DNA isolation and sequencing for WGS: 
DNA was isolated from peripheral blood Gentra Puregene Blood Kit (Qiagen, 
Germantown, MD, USA) or saliva collected using ORAgene Discover ORG-500 
(DNAgenoteck Ottawa, ON, Canada). Sequencing libraries were created for each 
individual sample following manufacturer’s protocol (Illumina protocol Preparing 
Samples for Sequencing Genomic DNA, p/n 11251892 Rev. A). Sequencing was 
performed on an Illumina HiSeq X with 100bp paired-end reads at the Baylor Miraca 
Genetics Laboratories. The base-calling was performed using the real-time analysis 
(RTA) software provided by Illumina. 
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Data analysis for WGS:  
The sequence reads FASTQ files were aligned to the human reference genome 
(GRCh37/hg19 Feb. 2009 assembly) using BWA (Burrows-Wheeler Alignment Tool) [3]. 
PCR duplicates were marked by Picard. GATK (Genome Analysis ToolKit) was used to 
realign INDELs, recalibrate quality scores, call, filter, recalibrate and evaluate variants 
(single-nucleotide variants (SNVs) and INDELs). SPLITREAD [4]  and CoNIFER [5] 
were used to call structural variants (SVs). 
Quality control:  
For each sample, SNVs and small INDELs were evaluated to determine if they 
fall within normal human genomic variation quality parameters (total number of variants, 
concordance rate, het/homo ratio, Ti/Tv ratio). Coverage of the sex chromosomes were 
assessed for each sample to confirm match with the reported karyotype. Mendelian 
errors (errors that lead to genotypes incompatible with Mendelian inheritance) were 
checked to confirm the relationship between family members.  
Sanger validations:  
It was previously demonstrated that variants with a QUAL score (a scaled 
probability of a variant existing at a given site based on the sequencing data, calculated 
using GATK variant caller) of 500 or higher are highly accurate [5]. Variants of interest 
with a QUAL score lower than 500 and all INDELs were confirmed by Sanger 
sequencing.  
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Variant annotation for SNVs and INDELs:  
Variants were annotated using VarSeq (GoldenHelix, USA). Each variant was 
annotated with information including gene names and accession numbers, reference 
variant, variant consequences (e.g., missense, frameshift), amino-acid changes, 
conservation scores, MAF, expression pattern, CADD scores [6], Polyphen [7] and SIFT 
[8] used for predicting the deleteriousness of single nucleotide and small indel variants.  
Genome sequencing variant filtering:  
We first searched for rare causal risk alleles that are fully penetrant with a high 
genetic relative risk. A recessive model was considered for homozygous, hemizygous 
and compound heterozygous variants and a dominant model was considered for de 
novo variants and inherited heterozygous variants from the opposite sex parent (e.g, 
when an affected 46,XX male inherited a heterozygous variant from his 46,XX mother). 
Step 1: Common variants with MAF > 1% were filtered out. Population frequency data 
was retrieved from dbSNP and NHLBI Exome Sequencing Project (ESP) Exome Variant 
Server (EVS) for SNVs and INDELs and the DGV database of genomic variants for 
structural variants. Variants that are repeatedly called within the sample set of the 97 
trios at >10% were also filtered out (unless the variant was only observed in the patient 
group) to remove variants that are most likely technical false positives. Step2: Within the 
exome, synonymous variants were filtered out. Step 3: Since ExAC (Exome 
Aggregation Consortium) database is reported to not have included pediatric cases with 
significant birth defect, de novo, homozygous, hemizygous, heterozygous or compound 
heterozygous variants observed in >4 individuals in ExAC (Exome Aggregation 
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Consortium) as heterozygous were filtered out. The identified variants were segregated 
into 6 types (Table 4-2). 
Results 
NGM in Duchenne Muscular Dystrophy 
 Next generation mapping is a new emerging tool in the market of genetics that 
still needs to prove its worth within the diagnostic arena. Previously, Bionano’s Irys 
technology has been mostly used for de novo assemblies of genomes with absent or 
incomplete reference. More recently, we and other laboratories saw the potential of this 
technology to identify large structural variants (SVs) such as insertions, deletions, 
inversions, balanced translocations and repeats on a clinical diagnostic level. However, 
due to its novelty and unproven track record in the clinics, we sought to validate the 
method of identifying large SVs in a cohort of patients diagnosed with Duchenne 
muscular dystrophy (DMD) (Table 4-3). These patients were known to carry multiple 
exon deletions or insertions in the Dystrophin gene as well as a large inversion that 
disrupted the DMD gene function. We used Bionano’s Irys next generation mapping 
system to validate its capability of identifying large, previously known SVs in DMD 
cases. 
 We performed next-generation mapping on cases diagnosed with DMD as well 
as on cases where carrier status for the mutation was a possibility, such as in mothers 
of affected males. Our validation cohort size comprised of a total of 9 affected DMD 
individuals (6 with deletions, 2 with insertions and 1 with an inversion) and 4 biological 
mothers, some of whom were known carriers of pathogenic DMD variants (Table 4-3). 
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Long DNA molecules were represented well throughout the genome, except in locations 
with few unique sequences such as centromeres, acromeres and long arm of Y 
chromosome (Figure 4-4). The size of the insertions and deletions that can be identified 
is dependent upon the length of the labeled DNA molecules and content of fragile sites, 
where endonuclease nicking sites are close to each other on both strands of DNA 
resulting in double stranded DNA break. Both of these issues will be addressed in a 
second version of the optiDNA preparation kits that are going to be released during the 
second half of 2017. In the new protocol DNA is stabilized in agarose, allowing for less 
manual manipulation, and a second endonuclease is used to allow for molecular 
representation of the regions where the first enzyme had double strand breaks due to 
fragile sites allowing for a better breakpoint resolution. 
  On average we were able to identify 1500 insertions, 750 deletions, 40 
inversions and 20 translocations per single case in the DMD cohort (Table 4-4). A 
distribution of the lengths of identified SVs is shown in Figure 4-4. Most of the identified 
insertions and deletions in the DMD cohort fell under 50kb in size; however, when 
considering SVs greater than 50kb in size, more deletions were identified in comparison 
to insertions. To interpret those variants and identify rare pathogenic variants, we 
needed a reference database to filter out the common benign variants. For that we used 
Bionano’s control database containing structural variant information from 144 healthy 
individuals. All variants seen in more than one individual from the control database, with 
at least 50% match in size of the structural variant, were filtered out. This filtration step 
allowed us to reduce the number of SVs to numbers allowing manual curation (Table 4-
5). A control database becomes extremely important for providing a genetic diagnosis in 
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patients where one doesn’t know the precise location on the genome where variants are 
associated with the disease of interest. Here, we showed that most of the structural 
variants are actually common and can be filtered out. 
 All previously known deletions in the DMD cohort were successfully identified 
using NGM (Figure 4-5). These cases had been clinically diagnosed using multiplex 
ligation dependent probe amplification (MLPA) that sequences all existing exons of 
DMD gene and identifies which exons are deleted. Unlike MLPA bionano’s NGM 
technology is capable of identifying the intronic breakpoints in the gene providing a 
more accurate representation of which part of the genome is missing in DMD cases. 
Also from Figure 4-5 we can see the ability of the instrument to identify a range of exon 
deletions, from a single exon deletion to multiple. The resolution of the breakpoints is 
limited to endonuclease nicking site density in a given location; higher density provides 
more accurate estimates. With a single enzyme the resolution of breakpoints is between 
3-5kb in size; however, it possible to gain higher accuracy with the use of a second 
endonuclease from 1.5 to 3kb. 
 We then tested whether NGM was capable of identifying not only 
hemizygous/homozygous deletions but also to determine carrier status of an individual 
by detecting heterozygous variants. We performed NGM using Irys in DMD duos 
(proband, mother) to determine if the mothers of the affected individuals were also 
carriers of the same variant. The first duo we examined (CDMD-1131-proband and 
CDMD-1132-mother) contained a large deletion in the DMD gene first identified in the 
proband by PCR and later confirmed by MLPA. The mother of this patient had been 
tested using array CGH to identify the possibility of the next child being affected with the 
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same disorder. The array CGH identified the same deletion in the mother that was 
present in the proband, which was also confirmed by MLPA. Our NGM testing of this 
duo confirmed the previous diagnosis of the proband, which we also confirmed by PCR 
(Figure 4-6A), and the carrier status of the mother (Figure 4-6B). We did not find a 
deletion in the mother of the second duo (who hadn’t been tested clinically), indicating 
that the mother is not a carrier of the deletion (Figure 4-7).  
In addition, two duos where exon 3-4 duplication had been identified by array 
CGH were tested. We identified this duplication in the both probands and it was also 
present in a heterozygous state in the mothers of affected males (Figure 4-8A,B). Since 
the carrier status of the mother hadn’t been determined clinically, we validated the NGM 
finding by quantitative PCR (Figure 4-9). 
 One of the defining features of Bionano’s NGM system is its capability to identify 
inversions, which cannot be detected with chromosomal microarrays. We had one 
patient diagnosed with DMD who carried a large 5.1Mb inversion in DMD gene that 
disrupted the protein starting from exon 38. The patient had undergone numerous tests 
in order to identify this 5.1Mb inversion. Standard tests for diagnosing DMD such as 
PCR sequencing for point mutations and MLPA for deletion/duplication analysis had 
been performed, both of which were negative. A muscle biopsy had been excised to 
perform RNA sequencing to identify if the mRNA had splicing issues. It was identified 
that mRNA was abnormally spliced, which suggested an inversion in the gene. Genome 
sequencing had then been performed to validate the RNA sequencing findings. 
Because genome sequencing is not a clinically validated test, a PCR was performed on 
a clinical basis and results reported to the patient and parents. We performed NGM on 
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this sample and were able to identify the 5.1Mb inversion in a fraction of the time and 
cost of previous tests (Figure 4-10). 
 Here, we have shown the capabilities of the NGM in identification of large 
pathogenic structural variants in a cohort of DMD patients with a clinical diagnosis. Next 
steps are to use this technology in cases where the location of the pathogenic variant is 
not known and try to find it. For that we have started to use this method on a number of 
disorders of sex development cases. 
NGM in Disorders of Sex Development 
 We performed Bionano NGM on 9 families diagnosed with a variety of 
undiagnosed DSD conditions (Table 4-6) to identify the underlying genetic diagnosis in 
conjunction with genome sequencing.  
 Unlike in Duchenne Muscular Dystrophy, where the genetic etiology is well 
defined and limited to the DMD gene on the X chromosome, CNVs in known DSD 
genes explain only a very small minority of cases. Therefore, in DSD cases, we do not 
know where to look for a pathogenic structural variant. To perform the analysis we first 
filtered out all common variants using the healthy control database consisting of 144 
individuals. As above, common variants were classified as being seen greater than 
once in the control database, with at least 50% overlap in the structural variant size or 
genome location breakpoint. Variant filtering based on frequency allowed us to 
significantly reduce the number of variants for manual curation (Table 4-7). The 
remaining variants were classified as rare or de novo based on the information available 
from the parents. To identify the likely causative variants, we used a DSD specific gene 
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list to filter structural variants based on gene overlap and proximity of the gene of 
interest to the structural variant. We were unable to find a structural variant with an 
effect on genes in the primary gene list that would explain the patients’ phenotypes as a 
first-pass clinical test. However, because for most of these families we have both 
genome mapping and genome sequencing we will be looking at the combination of the 
two to possibly identify compound heterozygous variants that may be pathogenic. 
These result were expected because not many structural variants in the genome are 
known to be associated with DSD. Using this method we hope to identify novel regions 
in the genome that may be associated with DSD. 
Discussion: 
For many years in modern genetic diagnostic the primary focus has been on 
single nucleotide variants and exome sequencing. However, a large subset of the 
human genome is missed when performing only exome sequencing – all the protein 
non-coding regions are not sequenced. This leaves a large gap in data collection and 
interpretation. More recently, due to continuous drop in sequencing price more 
institutions around the world choose to perform genome sequencing that is geared 
towards sequencing most of the human genome. Although this is a major step forward 
over exome sequencing it still has limitations, in particular because of the innate 
limitations of next-generation sequencing in terms of fragment lengths and unavailability 
of tools we are not able to identify of large structural variants. To overcome these 
limitations we used Bionano’s next generation mapping tools to look for larger structural 
variants in human genomes. 
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First, we used a cohort of patients diagnosed with Duchenne muscular dystrophy 
with a known structural variant in the DMD gene to validate the capability of the Irys 
system to accurately identify large deletions, insertions and inversions. We have had a 
100% success rate in identifying the correct clinically diagnosed structural variants 
using NGM, indicating the clinical utility of the method. Second, we used NGM to 
identify large pathogenic variants in patients with disorders of sex development of 
unknown genetic etiology. Although in the case of DSD we were not able to provide a 
genetic diagnosis, additional research with combination of genome sequencing might 
reveal variants causing the patient’s phenotype. NGM promises to help further our 
understanding of gene regulatory elements in the genome and how SNVs and SVs in 
these regions may affect gene regulation. For this reason we will in the future perform 
RNA sequencing on blood or skin-derived fibroblasts to see if any of the variants that 
we have identified outside of the coding regions of the genome, such as splice variants, 
intronic, intergenic and promoter variants have a deregulating effect of effect on gene 
expression. 
With the implementation of the exome sequencing as a clinical test for genetic 
diagnosis we were able to significantly increase the rate of diagnosis. However, as 
technologies have evolved over the past several years we can now get much longer 
read lengths of DNA molecules and in turn have a more complete picture of the human 
genome both on a single base pair resolution and globally for larger structural variants 
with comparable prices. It is important to look at the locations of the genome where we 
have much less understanding than the coding parts because many of the disease 
causing variants may be located outside of exons. The interpretation of pathogenicity of 
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non-coding variants will present challenges; however, with larger databases and gene 
expression studies the scientific community will be able to solve many more previously 
genetically undiagnosed cases. Although data not shown here, we will utilize genome 
sequencing data available on 97 trios to complement the analysis of NGM as it crucial 
to have the most complete sequence of the genome to provide genetic diagnosis. 
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Figures and Tables: 
 
Table 4-1: Primer sequences used for PCR and quantitative PCR for validation of 
structural variants identified in DMD cases 
 
 
 
 
Table 4-2: Genome sequence variant analysis steps 
 
1 SNVs+INDELs within protein-coding region of known DSD genes 
2 SNVs+INDELs outside protein-coding region (introns, promoters, UTRs) of 
known DSD genes 
3  SVs involving known DSD genes 
4 SNVs+INDELs within protein-coding region of genes not associated with 
DSD 
5  SVs involving 1 or more genes not associated with DSD 
6  De novo SNVs+INDELs outside the protein-coding region of genes not 
associated with DSD 
 
 
 
 
 
 
 
 
 
 
 
DMD Exon # Forward primer Reverse primer Product Size Annealing temperature
E2 tgcattttagATGAAAGAGAAGATG aaaacggatttttaagatacacagg 162bp 60°C
E3 ttcaaaaggggataatcgtga GCCTTCGAGGAGGTCTAGGA 152bp 60°C
E4 atgcctcacaggctctgttc GCAGTGCCTTGTTGACATTG 182bp 60°C
E5 cccctttctttaacagGTTGATT catttgtttcacacgtcaagg 294bp 60°C
E44 ctttTACCTGCAGGCGATTT cacccttcagaacctgatcttt 349bp 60°C
E45 catggggcttcatttttgtt TGACAGCTGTTTGCAGACCT 377bp 60°C
E46 gccatgtttgtgtcccagtt acCTTGACTTGCTCAAGCTTTT 349bp 60°C
E47 GCCAGGGAATTCTCAAACAA gaagcacccaggaaacaaaa 427bp 60°C
E48 tCCTTTCAGGTTTCCAGAGC CGTCAAATGGTCCTTCTTGG 387bp 60°C
E49 ttttccccagGAAACTGAAA tagtccacgtcaatggcaaa 303bp 60°C
E50 GATCTGAGCTCTGAGTGGAAGG ccaaagagaatgggatccag 126bp 60°C
E51 TCTGGTGACACAACCTGTGG CACCATCACCCTCTGTGATTT 434bp 60°C
E52 tacagGCAACAATGCAGGAT GCCTCTTGATTGCTGGTCTT 319bp 60°C
E53 GAATTCAGAATCAGTGGGATGA CCTCCTTCCATGACTCAAGC 413bp 60°C
E54 tagCAGTTGGCCAAAGACCT tcatggtccatccagtttca 356bp 60°C
E55 GAGAGGCTGCTTTGGAAGAA aagcggaaatgcctgactta 200bp 60°C
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Table 4-3: Cohort of patients diagnosed with Duchenne muscular dystrophy 
 
Cases with deletions in DMD gene are highlighted with red, insertions with green, and 
inversion with purple. Bolded cases indicate unaffected mothers of DMD probands. The 
coverage is defined as the total amount of the data produced in base pairs divided by 
the genome size (3.2 in case of humans). 
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Table 4-4: Number of structural variants identified in DMD cases 
 
 
 
Table 4-5: The remaining number of structural variants identified in DMD cases after 
filtering of common structural variants using a control database 
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Table 4-6: The cohort of DSD patients undergone NGM analysis 
 
 
 
 
Table 4-7: Number of structural variants identified by NGM in the DSD cohort after 
filtration of common variants from a control database containing 144 healthy individuals 
Data missing in cases in which structural variation has not been called yet. 
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Figure 4-1: DNA Nicking, Labeling, Repairing and Staining 
 
 
 
Figure 4-2: Irys Chip Nanochannel Structure and DNA Loading 
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Figure 4-3: Next generation mapping genome coverage. 
 
Vertical blue lines represent areas of the chromosome where long DNA molecules have 
been aligned. Below the blue lines are shown where traditional chromosome banding 
align. 
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Figure 4-4: Genome-wide distribution of insertions and deletion in the DMD cohort 
(probands and parents) 
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Figure 4-5: Deletions identified in DMD singletons  
For each case, the green bar represents the reference X chromosome. The blue bar 
represents the contig map generated based on long molecule assembly of the patient’s 
genome. The black vertical lines indicate endonuclease cut site. The lines between 
reference and assembled map show alignment of the two maps. The red area indicates 
deletion where reference (green) endonuclease sites are missing from the assembled 
map (blue). 
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Figure 4-6: A. DMD deletion identified in an 46,XY muscular dystrophy patient 
Top: Ref-seq locations on the X chromosome indicating possible size of the deletion 
based on MPLA and size identified by Irys 
Middle: Visual representation of the deletion 
Bottom: Confirmation of the deletion of exos 45-51 by PCR 
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Figure 4-6: B. DMD heterozygous deletion identified in a 46,XX mother of a DMD 
patient 
Top: Ref-seq locations on the X chromosome indicating possible size of the deletion 
based on MPLA and size identified by Irys 
Bottom: Visual representation of the deletion, showing one allele is wild type (top blue 
line) and one of the alleles has the deletion present in the proband (bottom blue line). 
Individual molecules represented by single orange lines on the bottom with black dots 
indicate nicking sites. 
 
 
 
 
 
 
141 
 
Figure 4-7: No DMD gene deletions identified in a mother (CDMD1158, blue) with an 
affected son. In this particular case several contigs (blue) are needed to cover the 
entirety of DMD gene, hence several sample maps (blue) shown in the image. 
 
Figure 4-8: A. Insertion identified in a DMD patient. (Color conventions are the same as 
in Fig. 4-6) 
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Figure 4-8: B. A heterozygous insertion identified in a mother of a DMD patient. (Color 
conventions are the same as in Fig. 4-6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
143 
 
Figure 4-9: Quantitative PCR validation of the DMD exon 3-4 duplication in the mother 
of patient CDMD-1163. Exons 2 & 4 are present in single copies on X chromosome, 
amounts in the proband (red). The mother (CDMD-1164), who has 2 X chromosomes, 
has 2x more DNA (green). Exons 3 & 4 are duplicated in the proband and mother DNA 
amount in proband (2 copies) is approximately 1.5x lower than in mother (3 copies) 
indicating duplication is present in both. 
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Figure 4-10: 5.1Mb inversion disrupting the protein function identified in DMD patient. 
The top row of the table shows the Ref-Seq locations of the inversion identified by 
genome sequencing. The bottom tow shows the location and size identified by Bionano 
NGM. Purple highlights on the reference show the locations of the genes, including 
DMD. The two lines across show that part of the sample map (blue) is aligning to the 
references in the opposite orientation, indicating and inversion of the entire middle 
section. 
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Chapter 5 
 
Conclusions 
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Exome/Genome Sequencing 
 
DNA sequencing has become a routine procedure in clinics across the United 
States and around the globe where physicians order either exome or single gene 
sequencing to identify pathogenic variants leading to patient’s phenotype and provide 
the appropriate care. The increased prevalence of exome and genome sequencing in 
clinical practice will improve the diagnostic yields of clinical next-generation sequencing. 
As more genomes are sequenced, associated with detailed phenotyping, our 
understanding of phenotype/genotype correlation will progress, allowing for a greater 
diagnostic yield from exome sequencing for single-gene or complex diseases. 
These considerations highlight the need for deep phenotyping and better 
genotype/phenotype correlation in DSD and other disorders. To this end, translational 
research networks will be crucial to generate evidence for and promote best practices in 
clinical care to achieve best possible health outcomes and quality of life for patients and 
their families. In particular the DSD-TRN has created the first DSD registry in the US to 
collect standardized clinical practice data and standardized measurements in all fields 
involved in clinical care for DSD families: genetic, psychosocial, endocrine, 
anatomy/surgery, etc. Data entered into the registry from all the network’s sites will be 
analyzed to try to derive new genetic etiologies for DSD, refine genotype/phenotype 
correlations and, eventually offer evidence-based recommendations for optimal 
practice. 
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Genome Mapping 
For many years in modern genetic diagnostic the primary focus has been on 
single nucleotide variants exome/genome sequencing. However, a large subset of the 
human genome is missed when performing only genome/exome sequencing – all the 
protein non-coding regions are not sequenced. This leaves a large gap in data 
collection and interpretation. More recently, due to continuous drop in sequencing price 
more institutions around the world choose to perform genome sequencing that is geared 
towards sequencing most of the human genome. Although this is a major step forward 
over exome sequencing it still has limitations, in particular because of the innate 
limitations of next-generation sequencing in terms of fragment lengths and unavailability 
of tools we are not able to identify of large structural variants. To overcome these 
limitations laboratories around the world will need to use next generation mapping tools 
to look for larger structural variants in human genomes. 
As DNA sequencing technologies have evolved and will continue to evolve the 
DNA sequence read lengths will become longer with higher quality enabling researchers 
and clinicians to see the more complete picture of the human genome both on a single 
base pair resolution and globally for larger structural variants. It is important to look at 
the locations of the genome where we have much less understanding than the protein 
coding regions because many of the unknown disease causing variants may be located 
outside of exons. The interpretation of pathogenicity of non-coding variants will present 
challenges; however, with larger databases and gene expression studies the scientific 
community will be able to solve many more previously genetically undiagnosed cases.  
 
 
 
149 
 
The upcoming clinical genetic diagnostic practice should consists of next 
generation mapping and sequencing technologies as a first line test (after life 
threatening conditions have been ruled out by other tests). The turnaround times will 
continue to improve and data analysis highly automated. This method will prove to be 
the most effective in identifying genetic diagnosis and providing a path towards 
acceleration of improvement of patient care. 
Identification of Novel Disease Genes 
There is no doubt that both genome sequencing and genome mapping have a 
potential for high diagnostic ability. These techniques are going to become the core of 
modern clinical genetics. However, many variants identified by either of the techniques 
will initially be uninterpretable clinically and be known as variants of unknown 
significance. The utilization of animal models will become of outmost importance to 
study VUS to improve the interpretive gap between identified variants and allowing the 
identification of novel genes involved in human disease pathogenesis. We have 
demonstrated this method in the case of 46,XY DSD. Were by utilizing undervirilized 
B6-YPOS mice as a model for 46,XY DSD allowed the identification of 15 novel 
candidate genes involved in male sex development.  
 
